Immatics在ESMO更新PRAME双抗与TCR-T早期数据，疗效积极但仍处早期且市场焦点在2027年三期读出

----- dp255472_6k.htm -----
6-K
1
dp255472_6k.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
October 24, 2026
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F
☒
Form 40-F
☐
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
IMA402 Data Release
On October 24, 2026, the Company announced updated clinical trial
data from its ongoing phase 1b study with IMA402 PRAME TCR bispecific (TCER
®
) in a heavily pretreated patient
population with a median of three prior lines of therapy.
Patient Population
. As of the
June 1, 2026 data cutoff, 126 heavily pretreated patients across multiple tumor types, primarily melanoma and ovarian cancer, received
at least one infusion of IMA402 during the dose escalation or dose expansion part of the ongoing trial (NCT05958121). Patients had received
a median of three prior lines of systemic treatment (range: 0 – 7), had a median target lesion sum of diameter of 7.4 cm (range:
1.2 – 39.8) and had a median of four tumor lesions (range: 1 – 15). The efficacy population included 40 patients treated
within the recommended Phase 2 dose (RP2D) range of 10 to 45 mg across varying levels of PRAME expression. Within this population, 31
patients exhibited high PRAME expression levels (PRAME-high)
1
in their tumors. Of these,
all patients with PRAME-high melanoma had received prior systemic treatment with immune checkpoint inhibitors (“ICI”), with
a median of 2 prior ICI-regimens and all patients with PRAME-high ovarian cancer were previously treated with platinum-based chemotherapy.
Of the 31 patients exhibiting high PRAME expression, 22 were melanoma patients, 20 of which received monotherapy and two received the
combination of IMA402 and pembrolizumab.
Safety Data
. IMA402 showed favorable tolerability across all
doses. The most frequent treatment-related adverse events (“TRAEs”) were expected, transient lymphopenia and low-grade cytokine
release syndrome (“CRS”), consistent with the mechanism of action. No cases of Immune Effector Cell-Associated Neurotoxicity
Syndrome (“ICANS”) were reported. No IMA402-related Grade 5 events were reported. Tolerability was consistent across all evaluated
doses, including the RP2D range, with no additive toxicity observed when combined with an ICI.
The following table shows TRAEs across all indications and dose levels:
1
Patients showed PRAME expression 3-fold higher
than the PRAME qPCR threshold, based on an exploratory analysis in the efficacy population. More than 80% of patients with cut. melanoma
are estimated to have PRAME-high expression based on Immatics and TCGA RNA seq data.
a
TRAEs: All treatment-emergent adverse events at least
possibly related to IMA402 with grade 1-2 occurring in at least 9 patients (incidence ≥7.1%), and all events with grade 3-5. One uncoded
grade 1 AE (“spotting”) is not included. Abdominal pain incudes “Abdominal Pain” and "Abdominal Pain Upper”;
Patients are counted only once per adverse event.
The following table shows TRAEs for IMA402 as monotherapy and IMA402
with pembrolizumab at all dose levels:
a
TRAEs: All treatment-emergent adverse events at least
possibly related to IMA402 with grade 1-2 occurring in at least 8 patients for monotherapy (incidence ≥7%), and all events with grade
3-5. One uncoded grade 1 AE (“spotting”) is not included. Abdominal pain incudes “Abdominal Pain” and "Abdominal
Pain Upper”; Patients are counted only once per adverse event.
b
Out of 19 patients treated with IMA402 + pembrolizumab,
3 have ongoing early step dosing and did not yet reach their target dose and 6 did not have the opportunity of at least 3 months of follow-up.
Of the remaining 10 patients, 3 were treated with IMA402 below 10 mg, 2 were PRAME negative, and 1 had LDH >1.5x ULN. ALT, alanine
aminotransferase; AST, aspartate aminotransferase.
The following table shows TRAEs for IMA402 as monotherapy with and
without pembrolizumab for the efficacy population:
a
TRAEs: All treatment-emergent adverse events at least
possibly related to IMA402 with grade 1-2 occurring in at least 4 patients (incidence ≥10%), and all events with grade 3-5. One uncoded
grade 1 AE (“spotting”) is not included. Patients are counted only once per adverse event.. ALT, alanine aminotransferase;
AST, aspartate aminotransferase.
Anti-Tumor Activity and Durability
. IMA402 showed promising
anti-tumor activity as monotherapy (n=36) or in combination with an immune checkpoint inhibitor (n=4) in the efficacy population at RP2D
range. Treatment with IMA402 demonstrated 10 confirmed responses resulting in an overall confirmed objective response rate (“cORR”)
of 25% (10/40) and a disease control rate (DCR) of 63% (25/40). This includes one confirmed complete response in melanoma. The longest
ongoing response exceeded 2 years. In the PRAME-high population, cORR was 32% (10/31) across all indications and 32% (7/22) in patients
with melanoma. The PRAME-high melanoma population further showed a median duration of response (“mDOR”) of 12.5 months, with
a median follow-up time (“mFU”) of 16.8 months. Median overall survival (“mOS”) was not reached (mFU 8.8 months),
with 91% of patients alive at 1 year (versus 60% of patients treated below RP2D range), indicating promising overall survival data irrespective
of best response. Among 6 patients with PRAME-high ovarian cancer, 3 confirmed responses were reported.
a
Includes cutaneous melanoma and one patient with uveal
melanoma.
b
Includes endometrial cancer (n=2), sqNSCLC (n=2), and synovial sarcoma (n=1); BOR, best overall response; BL, baseline;
cCR, confirmed complete response; cORR, confirmed objective response rate; DCR, disease control rate; PD, progressive disease; (c)PR,
(confirmed) partial response; SD, stable disease.
BOR, best overall response; BL, baseline; cCR, confirmed complete
response; cORR, confirmed objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease.
Next Development Steps
The promising clinical profile of IMA402 supports a development path
across various solid tumors in earlier and later treatment lines. These include combination approaches with ICIs in melanoma and in gynecologic
cancers as well as IMA402 in combination with the Company’s MAGEA4/8-directed bispecific, IMA401, in lung cancer with first data
expected in 2027. Furthermore, the use of Immatics’ proprietary rapid, sensitive and reliable liquid biopsy-based PRAME testing
enables precise patient selection and could support potential fast-to-market strategies, subject to regulatory approval, in PRAME-high
melanoma and beyond.
Anzu-cel Poster Presentation
On October 23, 2026, additional exploratory analyses (data cutoff September
24, 2025) of anzu-cel (anzutresgene autoleucel, IMA203), presented in a poster (2128P) by Sapna Patel, M.D., demonstrated durable clinical
benefit following a one-time treatment in a heavily pretreated population of patients with advanced melanoma. Durable clinical benefit
was observed across patients with varied baseline clinical and treatment characteristics, with no single characteristic identified as
a predictor of prolonged PFS. Exploratory analyses suggested that lower tumor burden, lower LDH, and a higher effector-to-target ratio
may be associated with longer PFS. These findings further strengthen the clinical profile of anzu-cel, which is currently being evaluated
in the Phase 3 SUPRAME trial in advanced melanoma.
* * *
Certain statements in this report may be considered forward-looking
statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance.
For example, statements concerning timing of data read-outs for product candidates, the timing, outcome and design of clinical trials,
the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing and outcomes of IND,
CTA, BLA and other regulatory filings, or the timing of commercial launches, estimated market opportunities of product candidates, manufacturing
timetables, capacity and success rates, the potential benefits of product candidates, the Company’s focus on partnerships to advance
its intended strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”,
“will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”
or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements
are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied
by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable
by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible
to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include,
but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties
and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission
(SEC). Nothing in this report should be regarded as a representation by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue
reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these
forward-looking statements. All the scientific and clinical data presented within this report are – by definition prior to completion
of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary
source data verification.
* * *
In connection with the foregoing, the Company issued a press release,
copy of which is attached hereto as Exhibit 99.1, made available presentations, copies of which are attached hereto as Exhibits 99.2 and
99.3, and made available an updated corporate presentation, a copy of which is attached hereto as Exhibit 99.4.
INCORPORATION BY REFERENCE
This Report on Form 6-K (other than the exhibits hereto) shall be deemed
to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-240260, 333-274218 and 333-286151)
of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports
subsequently filed or furnished.
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated October 24, 2026
99.2
Initial Results With IMA402, a PRAME-Targeted T-cell Receptor (TCR)-based Bispecific T-cell Engager (TCER) in Advanced Solid Tumors
99.3
Response Durability with Anzutresgene Autoleucel (Anzu-cel), a PRAME-directed T-cell Receptor T-cell Therapy, in Advanced Melanoma
99.4
Corporate presentation dated October 24, 2026
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
IMMATICS N.V.
Date: October 26, 2026
By:
/s/ Harpreet Singh
Name:
Harpreet Singh
Title:
Chief Executive Officer

----- dp255472_ex9901.htm -----
EX-99.1
2
dp255472_ex9901.htm
EXHIBIT 99.1
Exhibit 99.1
PRESS RELEASE
Immatics
Presents Clinical Activity of IMA402 PRAME Bispecific and
IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in
Two Oral Presentations at 2026 ESMO Annual Meeting
·
IMA402 PRAME bispecific continues to demonstrate
encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile
·
IMA402 achieved a cORR of 32%, 12.5 months median
DOR and a 1-year OS rate of 91% in advanced melanoma patients with high PRAME expression
·
Clinical profile of IMA402 reinforces development
path across multiple solid tumor indications, including melanoma, gynecologic cancers and lung cancer, in earlier and later treatment
lines, supported by Immatics’ innovative, rapid liquid biopsy-based PRAME testing
·
IMA203CD8 PRAME cell therapy demonstrated deep
and durable anti-tumor activity across multiple tumor types with a manageable safety profile, supporting its tumor-agnostic potential.
At clinically relevant dose levels in patients with advanced, heavily pretreated gynecologic cancers, cORR was 55% with a median DOR of
8.4 months
Houston, Texas and Tuebingen, Germany, October
24, 2026
–
Immatics N.V
.
(NASDAQ: IMTX, “Immatics” or the “Company”),
the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today
announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8
PRAME cell therapy.
The IMA402 data will be presented in a rapid oral
presentation (1955RO) by Dirk Schadendorf, M.D., and the IMA203CD8 data were presented in an oral presentation (1946O) by Antonia Busse,
M.D., at the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid, Spain. In addition, exploratory analyses
of the anzu-cel Phase 1b melanoma cohort will be presented in a poster (2128P) by Sapna Patel, M.D. The slides are available in the ‘
Events
& Presentations
’ section of the Investor & Media page on the Company’s website.
“The data presented
at ESMO further underscore the potential of IMA402 as an off-the-shelf treatment option for patients with solid cancers. This promising
clinical profile reinforces our strategy as we continue to advance IMA402 across multiple cancer types and treatment lines,
Immatics Press Release October 24, 2026
1
| 7
with combination approaches
further expanding its reach,” said Cedrik Britten, M.D., Ph.D., Chief Medical Officer at Immatics. “In addition, as the IMA203CD8
PRAME cell therapy data continue to mature, we are increasingly encouraged by its broad potential for patients with advanced PRAME-positive
cancers. Together with anzu-cel, IMA402 and IMA203CD8 give us three distinct and complementary approaches to target PRAME, with the potential
to reach more patients across a broad range of cancers.”
Rapid Oral Presentation Summary - IMA402
PRAME TCR Bispecific Phase 1b Trial
Patient Population:
Heavily pretreated
patient population with a median of 3 prior lines of therapy
As of the data cutoff on June 1, 2026, 126 heavily
pretreated patients across multiple tumor types, primarily melanoma and ovarian cancer, received at least one infusion of IMA402 during
the dose escalation or dose expansion part of the ongoing trial (
NCT05958121
). Patients
had received a median of 3 prior lines of systemic treatment, had a median target lesion sum of diameter of 7.4 cm and had a median of
4 tumor lesions. The efficacy population included 40 patients treated within the recommended Phase 2 dose (RP2D) range of 10 to 45 mg
across varying levels of PRAME expression. Within this population, 31 patients exhibited high PRAME expression levels (PRAME-high)
1
in their tumors. Of these, all patients with PRAME-high melanoma had received prior systemic treatment with immune checkpoint inhibitors
(ICI), with a median of 2 prior ICI regimens and all patients with PRAME-high ovarian cancer were previously treated with platinum-based
chemotherapy.
Safety:
Favorable tolerability profile
as monotherapy and as combination therapy
IMA402 showed favorable tolerability across all
doses. The most frequent treatment-related adverse events (TRAEs) were expected, transient lymphopenia and low-grade cytokine release
syndrome (CRS), consistent with the mechanism of action. No cases of ICANS were reported. No IMA402-related Grade 5 events were reported.
Tolerability was consistent across all evaluated doses, including the RP2D range, with no additive toxicity observed when combined with
an ICI.
Anti-tumor Activity and Durability:
32%
cORR in PRAME-high melanoma with promising durability and survival
IMA402 showed promising
anti-tumor activity as monotherapy (n=36) or in combination with an immune checkpoint inhibitor (n=4) in the efficacy population at RP2D
range. Treatment with IMA402 demonstrated 10 confirmed responses resulting in an overall confirmed objective response rate (cORR) of 25%
(10/40) and a disease control rate (DCR) of 63% (25/40). This includes one confirmed complete response in melanoma. The longest ongoing
response exceeded 2 years. In the PRAME-high population, cORR was 32% (10/31) across all indications and 32% (7/22) in patients with melanoma.
The PRAME-high melanoma population further showed a median duration of response (mDOR) of 12.5 months (median follow-up, mFU, 16.8 months).
Median overall survival (mOS) was not reached (mFU 8.8 months), with 91% of patients alive at 1 year (versus 60% of patients treated below
RP2D range), indicating
1
Patients
showed PRAME expression 3-fold higher than the PRAME qPCR threshold, based on an exploratory analysis in the efficacy population. More
than 80% of patients with cut. melanoma are estimated to have PRAME-high expression based on Immatics and TCGA RNA seq data.
Immatics Press Release October 24, 2026
2
| 7
promising overall survival
data irrespective of best response. Among 6 patients with PRAME-high ovarian cancer, 3 confirmed responses were reported.
a
Includes cutaneous melanoma and one patient with uveal melanoma.
b
Includes endometrial cancer (n=2), sqNSCLC (n=2), and synovial
sarcoma (n=1); BOR, best overall response; BL, baseline; cCR, confirmed complete response; cORR, confirmed objective response rate; DCR,
disease control rate; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease.
BOR, best overall response; BL, baseline; cCR,
confirmed complete response; cORR, confirmed objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; SD,
stable disease.
Next Development Steps for IMA402:
The promising clinical profile of IMA402 supports
a development path across various solid tumors in earlier and later treatment lines. These include combination approaches with ICIs in
melanoma and in gynecologic cancers as well as IMA402 in combination with the Company’s MAGEA4/8-directed bispecific, IMA401, in
lung cancer with first data expected in 2027. Furthermore, the use of Immatics’ proprietary rapid, sensitive and reliable liquid
biopsy-based PRAME testing enables precise patient selection and could support potential fast-to-market strategies, subject to regulatory
approval, in PRAME-high melanoma and beyond.
Immatics Press Release October 24, 2026
3
| 7
Oral Presentation Summary - IMA203CD8 PRAME
Cell Therapy Phase 1 Trial
Patient population:
Heavily pretreated
patient population with limited treatment options
As of the data cutoff on August 7, 2026, 98 heavily
pretreated patients across multiple advanced solid tumor types expressing PRAME that had undergone a median of 3 prior systemic treatments
were enrolled in the ongoing Phase 1 dose escalation/dose expansion trial (
NCT03686124
).
Of these, 90 patients were evaluable for efficacy, including 27 with gynecologic cancers (ovarian and uterine cancer), 44 with melanoma,
12 with synovial sarcoma and 7 with other solid tumor types. All patients with ovarian cancer had received prior platinum-based therapy.
Safety:
Treatment with IMA203CD8 was
manageable
IMA203CD8 demonstrated a consistent and manageable
safety profile across different solid tumor types and a wide dose range (median dose 1.81x10
9
TCR T cells, range 0.44-12.50x10
9
).
The most frequent treatment-emergent adverse events (TEAEs) were expected and included transient cytopenias associated with the lymphodepletion
regimen and low-grade cytokine release syndrome (CRS), consistent with the mechanism of action. ICANS was infrequently observed, and no
IMA203CD8-related Grade 5 events occurred. Maximum tolerated dose (MTD) was not reached with doses up to 12.5 billion IMA203CD8 cells.
Anti-tumor Activity and Durability:
One-time
infusion of IMA203CD8 PRAME cell therapy showed anti-tumor activity across multiple tumor types
Across all evaluated dose levels and tumor types,
including lower dose levels not selected for further clinical development, a one-time infusion of IMA203CD8 demonstrated an ORR of 51%
(46/90) and a cORR of 41% (36/87). The DCR was 82% (74/90) and 83% (71/86) of patients with evaluable target lesions experienced tumor
reduction. Responses were observed across multiple solid tumors expressing PRAME, including ovarian cancer, uterine cancer, melanoma,
synovial sarcoma, and others. Durable long-term responses were observed with ongoing responses for more than 2.5 years.
3 patients without any post-baseline scan not
evaluable for assessment of tumor reduction, not depicted in the plot, but included in efficacy calculations. For patients achieving a
(c)CR with <100% change from baseline, target lesions were lymph nodes that resolved to <10 mm per RECIST 1.1; BOR, best overall
response; (c)CR, (confirmed) complete response; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease.
Immatics Press Release October 24, 2026
4
| 7
In 20 patients with gynecologic
cancers (ovarian and uterine cancer) treated at clinically relevant dose levels (≥DL4c), IMA203CD8 demonstrated consistent anti-tumor
activity with an ORR of 60% (12/20) and a cORR of 55% (11/20), a DCR of 70% (14/20) and tumor reduction in 68% (13/19) of patients. Early
durability data showed a mDOR of 8.4 months (mFU 6.0 months), a mPFS of 5.8 months (mFU 8.1 months) and mOS not reached at 7.8 months
mFU.
1 patient without any
post-baseline scan not evaluable for assessment of tumor reduction, not depicted in plot, but included in efficacy calculations; those
patients achieving a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm per RECIST
1.1; BOR, best overall response; (c)CR, (confirmed) complete response; PD, progressive disease; (c)PR, (confirmed) partial response; SD,
stable disease.
Next Development Steps for IMA203CD8:
Phase 1a dose escalation
is complete. Immatics is currently enrolling patients with uterine cancer at clinically relevant doses to further expand the clinical
dataset in this indication. In addition, a Phase 1/2 investigator-initiated trial (IIT) in patients with PRAME-positive pediatric cancers
is planned to start in 1H 2027. The clinical activity of IMA203CD8 observed across tumor types with distinct biology and differing levels
of PRAME expression, including ovarian cancer, uterine cancer, melanoma and synovial sarcoma, supports the broad applicability of IMA203CD8
across PRAME-positive cancers. The development approach for IMA203CD8 will leverage targeted cohorts of selected tumor types, such as
ovarian cancer, uterine cancer, rare cancers and pediatric cancers to build the clinical evidence base for broader, tumor-agnostic application.
Poster Presentation Summary – Anzu-cel
Phase 1b Melanoma Cohort
Additional exploratory
analyses (data cutoff Sept 24, 2025) of anzu-cel (anzutresgene autoleucel, IMA203), presented in a poster (2128P) by Sapna Patel, M.D.,
demonstrated durable clinical benefit following a one-time treatment in a heavily pretreated population of patients with advanced melanoma.
Durable clinical benefit was observed across patients with varied baseline clinical and treatment characteristics, with no single characteristic
identified as a predictor of prolonged PFS. Exploratory analyses suggested that lower tumor burden, lower LDH, and a higher effector-to-target
ratio may be associated with longer PFS. These findings further strengthen the clinical profile of anzu-cel, which is currently being
evaluated in the Phase 3 SUPRAME trial in advanced melanoma.
Immatics Press Release October 24, 2026
5
| 7
About IMA402 PRAME
Bispecific
IMA402 is a molecule from
Immatics’ TCR bispecifics (TCER
®
) pipeline directed against an HLA-A*02:01-presented peptide derived from PRAME.
IMA402 is currently being evaluated in a Phase 1b clinical trial in patients with solid tumors expressing PRAME. IMA402 is part of Immatics’
strategy to leverage the full clinical potential of targeting PRAME, one of the most promising targets for TCR-based therapies.
About IMA203CD8 PRAME
Cell Therapy
I
MA203CD8
is Immatics’ PRAME-directed TCR T-cell therapy engineered to recognize an intracellular PRAME-derived peptide presented by HLA-A*02:01
on the cell surface and initiate a potent and specific anti-tumor response. Co-transduction of CD8αβ with the PRAME TCR adds
functional CD4+ T cells designed to boost anti-tumor activity. IMA203CD8 is currently being evaluated in a Phase 1b clinical trial in
solid tumors expressing PRAME.
About Anzu-cel PRAME
Cell Therapy
Anzu-cel (anzutresgene
autoleucel; IMA203) is a PRAME-directed TCR T-cell therapy engineered to recognize an intracellular PRAME-derived peptide presented by
HLA-A*02:01 on the cell surface and initiate a potent and specific anti-tumor response. Anzu-cel PRAME cell therapy is currently being
evaluated in a registration-enabling randomized controlled Phase 3 trial, “SUPRAME,” in patients with unresectable or metastatic
melanoma who have disease progression on or after treatment with at least one checkpoint inhibitor. In parallel, the Phase 1/2 clinical
trial is ongoing with a focus on uveal melanoma.
About PRAME
PRAME is a tumor-associated target expressed in
more than 50 cancers. Immatics’ PRAME franchise includes multiple product candidates, therapeutic modalities, indications and combination
approaches: anzu-cel (anzutresgene autoleucel; IMA203) and IMA203CD8, both PRAME-directed cell therapies, and IMA402, a PRAME-directed
bispecific. Combination approaches include IMA402 with immune checkpoint inhibitors, IMA402 with the MAGEA4/8-directed bispecific IMA401,
and anzu-cel in combination with Moderna’s PRAME mRNA therapy designed to enhance the cell therapy response.
About Immatics
Immatics is committed to making a meaningful impact
on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers.
Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities,
spanning TCR T-cell therapies and TCR bispecifics.
Immatics
intends to use its website
www.immatics.com
as a means of disclosing material non-public information. For regular updates, you
can also follow us on
LinkedIn
and
Instagram
.
Forward-Looking Statements
Certain statements in
this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s
future financial or operating performance. For example, statements concerning timing of data read-outs, the timing, outcome and design
of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing and
outcomes of IND, CTA, BLA and other regulatory filings, the timing of commercial launches, estimated market
Immatics Press Release October 24, 2026
6
| 7
opportunities, manufacturing
timetables, capacity and success rates, the potential benefits of product candidates, the Company’s intended strategy, and other
metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”,
“should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives
of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management,
are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors
beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s
Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be
regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which
speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific
and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical
study report – preliminary in nature and subject to further quality checks including customary source data verification.
For more information, please contact:
Media
Trophic Communications
Phone: +49 151 74416179
immatics@trophic.eu
Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
InvestorRelations@immatics.com
Immatics Press Release October 24, 2026
7
| 7

----- dp255472_ex9902.htm -----
EX-99.2
3
dp255472_ex9902.htm
EXHIBIT 99.2
Exhibit 99.2
Initial Results With IMA402, a PRAME - Targeted T - cell Receptor (TCR) - based Bispecific T - cell Engager (TCER) in Advanced Solid Tumors Dirk Schadendorf 1 , Jessica C. Hassel 2 , Philipp Harter 3 , Ralf Gutzmer 4 , Mathilde Jalving 5 , Lisa Zimmer 6 , Yenny Angela 4 , Daniel Heudobler 7 , Frederik Marmé 8 , Brigitte Rack 9 , Tim Schutte 10 , Silvia Spoerl 11 , Gertraud Stocker 12 , Giovanna Fiore 13 , Kerstin Guenther 13 , Sarah Missel 13 , Olga Veremchuk 13 , Cedrik M. Britten 13 , Carsten Reinhardt 13 , Martin Wermke 14 Prof. Dr. Dirk Schadendorf Rapid Oral Presentation Abstract #8465 1 Clinic for Dermatology, University Hospital Essen, Essen, Germany; 2 University Hospital Heidelberg, Department of Dermatology, Heidelberg, Germany; 3 Kliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany; 4 Department of Dermatology, Johannes Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany; 5 Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands; 6 Dermatology, University of Duisburg - Essen, Essen, Germany; 7 Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany; 8 University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 9 Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany; 10 Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 11 Department of Internal Medicine - Haematology and Oncology, University Hospital Erlangen, Friedrich - Alexander - University Erlangen - Nürnberg (FAU), Erlangen, Germany; 12 Department of Oncology, Gastroenterology, Hepatology, and Pulmonology, University of Leipzig Medical Center, Leipzig, Germany ; 13 Immatics Biotechnologies GmbH, Tuebingen, Germany; 14 TU Dresden, Carl - Gustav - Carus Faculty of Medicine, NCT/UCC Early Clinical Trial Unit, Dresden, Germany Copies of this presentation obtained through QR, AR and/or text key codes are for personal use only and may not be reproduced without written permission of the authors
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 2 Declaration of Interests Advisory board, consulting, speaker’s honoraria: AstraZeneca, BioAlta , BioNTech, BMS, Boehringer Ingelheim, Daiichi Sankyo, EeBeTe , Formycon , ImCheck , Immatics , Immunocore, IOBioTech , Iovance , Ipsen, Merck - Serono, Moderna, MSD, Neracare , Novartis, Philogen , Pierre Fabre, Regeneron, Replimune , SkylineDx Research funding: BMS, MSD Prof. Dr. Dirk Schadendorf ; Abstract #8465
3 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Indication Cutaneous Melanoma Endometrioid Endometrial Carcinoma Uterine Carcinosarcoma Synovial Sarcoma Acral Melanoma Uveal Melanoma Mucosal Melanoma Endometrial Clear Cell Carcinoma Endometrial Serous Carcinoma Ovarian Serous Cystadenocarcinoma Ovarian Clear Cell Carcinoma Ovarian Endometrioid Carcinoma Head and Neck Salivary Duct Carcinoma Adenoid Cystic Carcinoma Neuroblastoma Malignant Rhabdoid Tumor Wilms Tumor (Nephroblastoma) Squamous Cell NSCLC Triple Negative Breast Carcinoma (TNBC) Cervical Adenosquamous Cell Carcinoma Large Cell Neuroendocrine Lung Carcinoma (LCNEC) Basal Cell Carcinoma Mucoepidermoid Carcinoma Large Cell Lung Carcinoma (LCLC) Spindle Cell Melanoma Testicular Germ Cell Tumor (Seminoma and Non - Seminoma) Myxoid Liposarcoma Angiosarcoma Small Cell Lung Cancer (SCLC) Esophageal Small Cell Carcinoma Cutaneous Squamous Cell Carcinoma Thymoma Merkel Cell Carcinoma Endometrial Sarcoma Esophageal Squamous Carcinoma Esophageal Adenosquamous Carcinoma Kidney Renal Papillary Cell Carcinoma Malignant Peripheral Nerve Sheath Tumor (MPNST) Cholangiocarcinoma Cervical Adenocarcinoma Head and Neck Salivary Gland Carcinoma Osteosarcoma HER2 - Enriched Breast Carcinoma Embryonal Rhabdomyosarcoma Adenosquamous NSCLC Diffuse Large B - cell Lymphoma (DLBCL) Sarcomatoid Carcinoma of the Lung Adenocarcinoma NSCLC Head and Neck Squamous Cell Carcinoma (HNSCC) Alveolar Rhabdomyosarcoma Ovarian Mucinous Carcinoma Adrenocortical Carcinoma Kidney Renal Clear Cell Carcinoma Hepatocellular Carcinoma Bladder Urothelial Carcinoma Cervical Squamous Cell Carcinoma Non - Squamous Anal Carcinoma Pancreatic Neuroendocrine Adenocarcinoma Prostate Neuroendocrine Adenocarcinoma Liposarcoma Undifferentiated Pleomorphic Sarcoma Acute Myeloid Leukemia (AML) Ewing Sarcoma Ovarian Leiomyosarcoma Breast Carcinoma, Luminal A Breast Carcinoma, Luminal B Squamous Anal Carcinoma Stomach Adenocarcinoma Esophageal Adenocarcinoma Fibrosarcoma Anaplastic Thyroid Carcinoma (…) IMA402 is an Optimized T - cell Engager (TCER) Designed to Target PRAME a Half - life calculated by non compartmental analysis (NCA). b Data on file: PRAME target prevalence is based on a proprietary mass spec - guided initial expression threshold applied to RNAseq and/or immunohistochemistry data (approximate values, values between 95% - 100% shown as 95%). NSCLC, non - small cell lung cancer; pHLA , peptide - human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; q2w, every 2 weeks; TCR, T - cell receptor . 1. Hofmann M, et al. mAbs . 2026;18(1):1 - 24. ≥95 % ≥10 % PRAME prevalence in selected indications % PRAME+ patients b Indication 95% Cutaneous Melanoma 95% Uterine Carcinoma 95% Uterine Carcinosarcoma 95% Synovial Sarcoma 90% Uveal Melanoma 90% Mucosal Melanoma 85% Ovarian Carcinoma Subtypes 70% Squamous Cell NSCLC 65% Triple - negative Breast Carcinoma 45% Small Cell Lung Cancer 45% Esophageal Carcinoma Subtype 40% Kidney Carcinoma Subtype 35% Cholangiocarcinoma 30% HER2 - Enriched Breast Carcinoma 25% Adenocarcinoma NSCLC 25% Head & Neck Squamous Cell Carcinoma 20% Hepatocellular Carcinoma 20% Bladder Carcinoma Improved benefit - risk profile with half - life extension 1 PRAME is expressed in more than 50 cancers Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. CD3/TCR Activated T cell Tumor Cell PRAME IMA402 x Antitumor Activity High - affinity and specificity TCR domain targeting PRAME pHLA molecules x Antibody - like format with half - life extension Long half - life of >1 week a allows for q2w or longer dosing intervals x Optimized tolerability Low - affinity T - cell recruiter against CD3/TCR allows higher dosing Prof. Dr. Dirk Schadendorf ; Abstract #8465
4 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. IMA402 - 101 Study Design Prof. Dr. Dirk Schadendorf ; Abstract #8465 EudraCT No. 2022 - 503133 - 54 - 00; NCT05958121. a Cutaneous melanoma, melanoma of unknown primary, uveal melanoma, synovial sarcoma, endometrial carcinoma, ovarian carcinoma, sq uamous non - small cell lung cancer. b Step dosing introduced at 0.36 mg, optimized step dosing: 0.03 mg/0.3 mg/10 mg/target dose, low - dose dexamethasone used as preventive measure for initial doses as applied for other bispecific T - cell engagers; abili ty to increase dose to previously cleared dose levels. c Exploratory high dose in n=5. d Efficacy population: All patients treated within the RP2D range as of Mar 1, 2026 (who had the opportunity for at least 3 months follow - up or who discontinued early due to disease progression or death), tested positive for PRAME, received ≥4 infusions as defined per protocol (thereof 3 step doses, currently at 0.03 mg/0.3 mg/10 mg, and 1 target dose), and had LDH ≤1.5xULN . BLRM, Bayesian logistic regression model; ECOG, Eastern Cooperative Oncology Group; MABEL, minimum anticipated biological eff ect level; MTD, maximum tolerated dose; q1w, every week; q2w, every 2 weeks; RP2D, recommended phase 2 dose. Data cutoff Jun 1, 2026 Key Eligibility Criteria Key Objectives Primary: • Determine MTD and/or RP2D • Assess safety and tolerability Secondary: • Evaluate initial antitumor activity (RECIST 1.1 and iRECIST ) • Assess pharmacokinetics • Recurrent and/ ​ or refractory solid tumors expressing PRAME a • No prospective PRAME testing required • HLA - A*02:01 positive • ECOG performance status 0 - 1 • Received or not eligible for all available indicated standard of care treatments • MABEL - based starting dose • Dose escalation based on cohorts of 1 - 6 patients using adaptive design (BLRM model) • MTD not reached per adaptive BLRM model • q1w step dosing (3 doses) up to target dose b • q2w dosing from week 7 introduced post data cutoff based on favorable pharmakokinetics • IMA402 RP2D range: 10 - 45 mg Phase 1 0.36 mg 0.8 m g 3 m g 5 m g 0.12 mg 1.6 mg 0.06 mg 0.02 mg 8 mg 4 mg 12 mg 20 mg 30 m g 10 m g 45 m g c Efficacy Population d (n=40) Safety Population (N=126) IMA402 Monotherapy IMA402 + Pembrolizumab 10 m g + pembrolizumab 5 m g + pembrolizumab 2 0 m g + pembrolizumab 30 m g + pembrolizumab
5 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Demographics: Heavily Pretreated Patient Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; sqNSCLC , squamous non - small cell lung cancer; ULN, upper limit of normal. Efficacy Population Safety Population n=40 N=126 Baseline Characteristics 27 - 26, 1, 0 8 5 - 2, 2, 1 78 - 62, 13, 3 31 17 - 7, 6, 4 Indication, n Melanoma - cutaneous, uveal, unknown primary Ovarian cancer Other - endometrial cancer, sqNSCLC, synovial sarcoma 59 (29 - 77) 60 (21 - 82) Age Median (range) 25 (63) 15 (38) 78 (62) 48 (38) ECOG performance status 0, n (%) 1, n (%) 10 (25) 57 (45) LDH at baseline >1xULN, n ( %) 7.9 (1.5 - 19.4) 7.4 (1.2 - 39.8) Baseline tumor burden Median target lesion sum of diameter (cm) (range) 4 (2 - 10) 11 (28) 3 (8) 4 (1 - 15) 44 (35) 7 (6) Tumor lesions Number of lesions, median (range) Liver metastases, n (%) Brain metastases, n (%) Treatment Experience 3 (0 - 6) 3 (0 - 7) No. of prior lines of systemic treatment Median (range) 19 (48) 31 (78) 18 (45) 60 (48) 89 (71) 60 (48) Prior systemic treatments, n (%) Chemotherapy ICI Targeted therapy Data cutoff Jun 1, 2026
6 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Safety Profile Across All Indications and Dose Levels (N=126) Prof. Dr. Dirk Schadendorf ; Abstract #8465 a TRAEs: All treatment - emergent adverse events at least possibly related to IMA402 with grade 1 - 2 occurring in at least 9 patient s (incidence ≥7.1% ) , and all events with grade ≥ 3. One uncoded grade 1 AE (“ spotting ”) is not included. Abdominal pain includes “Abdominal Pain” and "Abdominal Pain Upper ”; Adverse events are coded using the MedDRA Version 26.0. Grades are determined according to National Cancer Institute CTCAE, version 5.0, except grades for CRS and ICANS which are determine d a ccording to Lee et al., 2019; Neelapu et al., 201 9 and tumor lysis syndrome which is determined according to Cairo and Bishop, 2004. Patients are counted only once per adverse event. Data cutoff Jun 1, 2026 • Most frequent related AEs were: • Transient lymphopenia (resolved within a median of 5d) • Low - grade CRS • One CRS G4 event at 0.08 mg starting dose only; no further CRS G4 events after step dose optimization • One CRS G3 event at 0.03 mg starting dose only, completely resolved within 7d • No ICANS observed • No IMA402 - related G5 events No additive toxicity was observed in patients treated with IMA402 + pembrolizumab (see appendix) AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRS, cytokine release syndrome; ICANS, imm une effector - cell associated neurotoxicity syndrome; TEAE, treatment - emergent AE; TRAE, treatment - related AE. ≥ Grade 3 All Grades Treatment - related AEs, n (%) a 44 (35) 56 (44) Lymphopenia 2 (2) 46 (37) Cytokine release syndrome 2 (2) 42 (33) Arthralgia 1 (1) 32 (25) Fatigue 10 (8) 23 (18) ALT/AST increased 0 18 (14) Pruritus 0 18 (14) Pyrexia 4 (3) 17 (13) Anaemia 1 (1) 17 (13) Myalgia 0 16 (13) Rash 4 (3) 12 (10) Gamma - glutamyltransferase increased 1 (1) 10 (8) Nausea 0 10 (8) Erythema 4 (3) 9 (7) Lipase increased 0 9 (7) Diarrhoea 1 (1) 9 (7) Abdominal pain 3 (2) 4 (3) Hypertension 1 (1) 4 (3) Leukopenia 1 (1) 4 (3) Vomiting 1 (1) 3 (2) Blood creatinine increased 1 (1) 3 (2) Tumour pain 2 (2) 2 (2) Neutropenia 1 (1) 2 (2) Back pain 1 (1) 2 (2) Pancreatitis 1 (1) 2 (2) Stomatitis 1 (1) 2 (2) Urinary tract disorder 1 (1) 1 (1) Acute kidney injury 1 (1) 1 (1) Electrocardiogram abnormal 1 (1) 1 (1) Herpes zoster 1 (1) 1 (1) Immune - mediated arthritis 1 (1) 1 (1) Liver function test increased 1 (1) 1 (1) Tumour lysis syndrome ≥ Grade 3 All Grades Treatment - emergent AEs, n (%) 81 (64) 125 (99) Any 65 (52) 120 (95) Treatment - related
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 7 Efficacy of IMA402 “ Pembrolizumab Across All Indications in the Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Includes cutaneous melanoma and 1 patient with uveal melanoma. b Includes endometrial cancer (n=2), sqNSCLC (n=2), and synovial sarcoma (n=1). BOR, best overall response; BL, baseline; cCR , confirmed complete response; cORR , confirmed objective response rate; DCR, disease control rate; ICI, immune checkpoint inhibitor; PD, progressive disease; (c )PR , (confirmed) partial response; SD, stable disease. Data cutoff Jun 1, 2026 IMA402 monotherapy IMA402 + pembrolizumab All Indications (n=40) 25% (10/40) cORR 63% (25/40) DCR (week 6) Melanoma a Ovarian cancer Other indications b BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing response/ disease control Ongoing treatment Confirmed responses in ICI - pretreated melanoma and platinum - pretreated ovarian cancer
8 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Exploratory Analysis of PRAME Levels and Disease Outcome in Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a PRAME low does not preclude response to IMA402, 1 cPR observed in a patient with PRAME low endometrial cancer below RP2D range; b Data on file: PRAME target prevalence is based on in - house (n=136) and TCGA RNAseq (n=473) analysis using proprietary mass spec - guided initial expression threshold. # Mann - Whitney U test . BOR, best overall response; cCR , confirmed complete response; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease; TCGA, The Ca nce r Genome Atlas. Data cutoff Jun 1, 2026 PRAME mRNA expression relative to threshold PRAME low : 1 - 3x expression level PRAME high : >3x expression level PRAME negative: below threshold • IMA402 shows association of higher PRAME levels with improved disease outcomes and tumor reduction • All responders a with melanoma are PRAME high • >80% b of patients with melanoma are PRAME high BOR (RECIST 1.1) PD SD PR cPR cCR n=40 Tumor Reduction Efficacy Population All Indications #
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 9 Efficacy Population n=40 PRAME low n=9 a PRAME high n=31 Melanoma n=22 IMA402 Monotherapy n=20 IMA402 + Pembrolizumab n=2 Ovarian Cancer n=6 Other b n=3 Patient Disposition Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Includes 2 patients treated with IMA402 + pembrolizumab. b Other includes endometrial cancer (n=2) and synovial sarcoma (n=1). c PRAME low does not preclude response to IMA402, 1 cPR observed in a patient with PRAME low endometrial cancer below RP2D range. d Data on file: PRAME target prevalence is based on in - house (n=136) and TCGA RNAseq (n=473) analysis using proprietary mass spec - guided initial expression threshold. qPCR, quantitative polymerase chain reaction. Data cutoff Jun 1, 2026 • Exploratory analysis in efficacy population based on qPCR expression levels • All responders c with melanoma are PRAME high • >80% d of patients with melanoma are PRAME high
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 10 Efficacy of IMA402 “ Pembrolizumab by PRAME Expression Prof. Dr. Dirk Schadendorf ; Abstract #8465 PRAME low (n=9) PRAME high (n=31) IMA402 monotherapy IMA402 + pembrolizumab Melanoma a Ovarian cancer Other indications b BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing response/ disease control Ongoing treatment Ovarian Cancer Melanoma All Indications 3/6 32% (7/22) 32% (10/31) cORR 3/6 73% (16/22) 65% (20/31) DCR (week 6) Data cutoff Jun 1, 2026 a Includes cutaneous melanoma and one patient with uveal melanoma. b Includes endometrial cancer (n=2), sqNSCLC (n=2), and synovial sarcoma (n=1). BOR, best overall response; BL, baseline; cCR , confirmed complete response; cORR , confirmed objective response rate; DCR, disease control rate; PD, progressive disease; (c)PR, (confirmed) partial response; RP 2D, recommended phase 2 dose; SD, stable disease. PRAME high
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 11 Durability of Responses in PRAME high Melanoma Prof. Dr. Dirk Schadendorf ; Abstract #8465 Ongoing patients were censored at the data cutoff for OS; OS rates were calculated using the Kaplan – Meier method. BOR, best over all response; BL, baseline; cCR , confirmed complete response; cORR , confirmed objective response rate; ICI, immune checkpoint inhibitor; mDOR , median duration of response; mFU , median follow up; mOS , median overall survival; PD, progressive disease; (c)PR, (confirmed) partial response; RP2D, recommended phase 2 dose; SD, sta ble disease. Data cutoff Jun 1, 2026 32% (7/22) cORR 12.5 mo 16.8 mo mDOR mFU All patients with melanoma in the efficacy population received prior ICI n=22 IMA402 + Pembrolizumab Not reached 8.8 mo mOS mFU 91% 1 - year OS rate Within RP2D range ( ≥ 10 mg), n=22 Below RP2D range (<10 mg), n=15 BOR (RECIST 1.1) PD Ongoing response/ disease control Ongoing treatment SD PR cPR cCR
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 12 Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • IMA402 is a novel TCR - based bispecific T - cell engager (TCER) targeting the cancer - associated antigen PRAME , a target expressed in more than 50 cancers • IMA402 demonstrates a favorable tolerability profile and encouraging initial antitumor activity across various indications, including melanoma HLA, human leukocyte antigen; ICI, immune checkpoint inhibitor; TCR, T cell receptor. Data cutoff Jun 1, 2026 In addition to IMA402 monotherapy, three ongoing cohorts of IMA402 with: MAGEA4/8 - directed TCER IMA401 Decitabine as potential PRAME enhancer Pembrolizumab or nivolumab/ relatlimab IMA402 Prof. Dr. Dirk Schadendorf ; Abstract #8465
Thank You – Trial Participants & Caregivers University Hospital Würzburg University Medical Center Utrecht Marien Hospital Düsseldorf Mühlenkreiskliniken Minden Klinikum Chemnitz Ev. Kliniken Essen - Mitte NCT Heidelberg University Hospital Regensburg University Medical Center Groningen Nuremberg General Hospital Leiden University Medical Center University Medical Centre Mannheim Comprehensive Cancer Center Ulm University Hospital Essen The Netherlands Cancer Institute University Cancer Center Leipzig University Hospital Magdeburg University Hospital TU Dresden Maps generated with ChatGPT - 5.6 Sol, 2026 University Hospital Erlangen UKGM Marburg Elbe Klinikum Buxtehude UKGM Gießen This study was funded by Immatics , Inc. Biostatistical support was provided by Yao Kou, MSc, with Immatics , Inc. Medical writing support was provided by Decera Clinical, funded by Immatics , Inc. Copies of this presentation obtained through QR, AR and/or text key codes are for personal use only and may not be reproduced without written permission of the authors Prof. Dr. Dirk Schadendorf ; Abstract #8465
APPENDIX Prof. Dr. Dirk Schadendorf ; Abstract #8465
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 15 Patient Disposition Prof. Dr. Dirk Schadendorf ; Abstract #8465 Data cutoff Jun 1, 2026 Safety Population N=126 Safety Population RP2D Range, PRAME+ n=48 Efficacy Population a n=40 PRAME low n=9 PRAME high n=31 Melanoma n=22 IMA402 Monotherapy n=20 IMA402 + Pembrolizumab n=2 Ovarian Cancer n=6 Other n=3 Not evaluable for efficacy: • Did not have the opportunity of at least 3 months of follow - up (n=6) • LDH >1.5x ULN (n=2) • Below RP2D range (n=52) • Ongoing early step dosing not yet reached target dose (n=3) • PRAME negative/not evaluable (n=23) • Cutaneous melanoma: n=5 • Ovarian cancer: n=2 • sqNSCLC : n=2 • Cutaneous melanoma: n=21 • Uveal melanoma: n=1 • Endometrial cancer: n=2 • Synovial sarcoma: n=1 a Efficacy population: All patients treated within the RP2D range as of Mar 1, 2026 (who had the opportunity for at least 3 mon ths follow - up or who discontinued early due to disease progression or death), tested positive for PRAME, received ≥4 infusions as defined per protocol (thereof 3 step doses, currently at 0.03 mg/0.3 mg/10 mg, and 1 target dose), and had LDH ≤1.5x ULN . LDH, lactate dehydrogenase; sqNSCLC , squamous non - small - cell lung cancer; RP2D, recommended phase 2 dose; ULN, upper limit of normal.
16 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Demographics in PRAME high Melanoma Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Excludes patients with uveal melanoma due to different staging guidelines. n=1 below RP2D range missing due to missing data e nt ry. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; ULN, upper limit of normal Data cutoff Jun 1, 2026 At RP2D Range (n=22) Below RP2D Range (n=15) 21 (9 5 ) 0 1 (5) 11 (73) 1 (7) 3 (20) Indication, n (%) Cutaneous melanoma Melanoma of unknown primary Uveal melanoma 5 7.5 (29 - 76) 62 (38 - 82) Age Median (range) 18 (82) 4 (18) 7 (47) 8 (53) ECOG performance status 0, n (%) 1, n (%) 5 (23) 6 (40) LDH at baseline >1xULN, n ( %) 8.0 (1.5 - 19.4) 6.7 (2.5 - 18.3) Baseline tumor burden Median target lesion sum of diameter (cm) (range) 3.5 (2 - 10) 7 (32) 3 (14) 6 (1 - 15) 6 (40) 1 (7) Tumor lesions Number of lesions, median (range) Liver metastases, n (%) Brain metastases, n (%) 4 (1 9 ) 1 7 (8 1 ) 0 1 1 (9 2 ) Metastatic staging, n (%) a IIIb/IIIc/IVM1a IVM1b/c/d Treatment Experience 3 (1 - 6) 2 (1 - 4) 4 (1 - 7) 2 (0 - 6) Prior lines of systemic treatment, median (range) Prior lines of ICI, median (range) 22 (100) 20 (91) 1 (5) 1 (5) 0 14 (93) 13 (87) 1 (7) 4 (27) 2 (13) Prior systemic treatments, n (%) ICI Ipilimumab + nivolumab Relatlimab + nivolumab TCR - based therapy PRAME - directed therapy
17 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Safety Profile of IMA402 Monotherapy and IMA402 + Pembrolizumab Prof. Dr. Dirk Schadendorf ; Abstract #8465 Data cutoff Jun 1, 2026 IMA402 Monotherapy (n=107) No additive toxicity was observed in patients treated with IMA402 + pembrolizumab ≥ Grade 3 All Grades Treatment - related AEs, n (%) a 36 (34) 46 (43) Lymphopenia 2 (2) 41 (38) Cytokine release syndrome 2 (2) 35 (33) Arthralgia 0 29 (27) Fatigue 10 (9) 20 (19) ALT/AST increased 0 17 (16) Pyrexia 1 (1) 16 (15) Myalgia 0 16 (15) Pruritus 4 (4) 14 (13) Anemia 0 14 (13) Rash 3 (3) 11 (10) Gamma - glutamyltransferase increased 1 (1) 10 (9) Nausea 4 (4) 9 (8) Lipase increased 1 (1) 9 (8) Abdominal pain 0 8 (7) Diarrhea 3 (3) 4 (4) Hypertension 1 (1) 4 (4) Leukopenia 1 (1) 4 (4) Vomiting 2 (2) 2 (2) Neutropenia 1 (1) 2 (2) Back pain 1 (1) 2 (2) Blood creatinine increased 1 (1) 2 (2) Pancreatitis 1 (1) 2 (2) Stomatitis 1 (1) 2 (2) Tumor pain 1 (1) 2 (2) Urinary tract disorder 1 (1) 1 (1) Acute kidney injury 1 (1) 1 (1) Electrocardiogram abnormal 1 (1) 1 (1) Herpes zoster 1 (1) 1 (1) Immune - mediated arthritis 1 (1) 1 (1) Liver function test increased 1 (1) 1 (1) Tumour lysis syndrome IMA402 + Pembrolizumab (n=19) b a TRAEs: All treatment - emergent adverse events at least possibly related to IMA402 with grade 1 - 2 occurring in at least 8 patients for monotherapy (incidence ≥7%), and all events with grade ≥3. One uncoded grade 1 AE (“ spotting ”) is not included. Abdominal pain incudes “Abdominal Pain” and "Abdominal Pain Upper ”; Adverse events are coded using the MedDRA Version 26.0. Grades are determined according to National Cancer Institute CTCAE , v ersion 5.0, except grades for cytokine release syndrome and Immune cell - associated neurotoxicity syndrome are determined accordi ng to Lee et al., 2019; Neelapu et al., 201 9 and tumor lysis syndrome which is determined according to Cairo and Bishop, 2004. Patients are counted only once per adverse eve nt. b Out of 19 patients treated with IMA402 + pembrolizumab, 3 have ongoing early step dosing and did not yet reach their target d ose and 6 did not have the opportunity of at least 3 months of follow - up. Of the remaining 10 patients, 3 were treated with IMA402 below 10 mg, 2 were PRAME negative, and 1 had LDH >1.5x ULN. ALT, alanine aminotransferase; AST, aspartate aminotransferase. ≥ Grade 3 All Grades Treatment - related AEs, n (%) b 8 (42) 10 (53) Lymphopenia 0 7 (37) Arthralgia 0 5 (26) Cytokine release syndrome 1 (5) 3 (16) Fatigue 0 3 (16) ALT/AST increased 0 3 (16) Anemia 0 3 (16) Erythema 0 2 (11) Arthropathy 0 2 (11) Dry skin 0 2 (11) Headache 0 2 (11) Pruritus 0 2 (11) Rash 1 (5) 1 (5) Gamma - glutamyltransferase increased 0 1 (5) Alopecia 0 1 (5) Atrial fibrillation 0 1 (5) Blood creatinine increased 0 1 (5) Blood thyroid stimulating hormone decreased 0 1 (5) Body temperature increased 0 1 (5) Decreased appetite 0 1 (5) Diarrhea 0 1 (5) Dysgeusia 0 1 (5) Herpes simplex reactivation 0 1 (5) Hyponatraemia 0 1 (5) Myalgia 0 1 (5) Oedema 0 1 (5) Oedema peripheral 0 1 (5) Pyrexia 0 1 (5) Thrombocytopenia 0 1 (5) Tumour pain 0 1 (5) Uveitis
18 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Safety Profile of the Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 IMA402 Efficacy Population ± Pembrolizumab (n=40) a TRAEs: All treatment - emergent adverse events at least possibly related to IMA402 with grade 1 - 2 occurring in at least 4 patient s (incidence ≥10%), and all events with grade ≥3. One uncoded grade 1 AE (“ spotting ”) is not included. Adverse events are coded using the MedDRA Version 26.0. Grades are determined according to National Cancer Institute CTCAE, version 5.0, except grades for cytokine release syndrome and Immune cell - associate d neurotoxicity syndrome are determined to Lee et al., 2019; Neelapu et al., 201 9 and tumor lysis syndrome which is determined according to Cairo and Bishop, 2004. Patients are counted only once per adverse event.. ALT, alanine aminotransferase; AST, aspartate aminotransferase. Data cutoff Jun 1, 2026 ≥ Grade 3 All Grades Treatment - related AEs, n (%) a 16 (40) 19 (48) Lymphopenia 1 (3) 17 (43) Arthralgia 0 15 (38) Cytokine release syndrome 1 (3) 14 (35) Fatigue 4 (10) 11 (28) ALT/AST increased 0 9 (23) Myalgia 2 (5) 8 (20) Gamma - glutamyltransferase increased 1 (3) 7 (18) Anemia 3 (8) 6 (15) Lipase increased 0 6 (15) Amylase increased 0 6 (15) Pruritus 0 5 (13) Blood alkaline phosphatase increased 0 5 (13) Diarrhea 0 5 (13) Erythema 0 5 (13) Pyrexia 1 (3) 2 (5) Leukopenia 1 (3) 1 (3) Back pain 1 (3) 1 (3) Herpes zoster 1 (3) 1 (3) Hypertension 1 (3) 1 (3) Liver function test increased 1 (3) 1 (3) Pancreatitis
19 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. CRS Dynamics Prof. Dr. Dirk Schadendorf ; Abstract #8465 • Favorable CRS profile with no > G2 CRS after first step dose • Median CRS onset from first IMA402 infusion in days (range) c : 1 (0 - 33) • Median d uration of CRS in days (range) d : 2 (1 - 12) Data cutoff Jun 1, 2026 G1 G2 G3 G4 5+ 4 3 2 1 Infusion 110 116 118 121 126 Patients exposed 0.02 - 45 mg 0.02 - 45 mg 0.02 - 10 mg 0.02 - 0.5 mg 0.02 - 0.12 mg Actual dose received b a a Plot shows adverse events with onset during the specified infusion. b Step dosing was introduced during dose escalation at a dose of 0.36 mg. Optimized step dosing is now at 0.03 mg/0.3 mg/ 10 mg /t arget dose. c Onset per CRS event (n=64), recurrent events analy z ed separately . d Duration per resolved CRS events at data cutoff (n=63), recurrent events analyzed separately. e 1 CRS G3 event at 0.03 mg starting dose only, completely resolved within 7d; 1 CRS G4 event at 0.08 mg starting dose only, no fu rther CRS G4 events after step dose optimization. CRS, cytokine release syndrome. 126 IMA402 safety population , n (%) 46 ( 37 ) A ny grade CRS 38 ( 30 ) Grade 1 6 ( 5 ) Grade 2 1 (1) Grade 3 e 1 (1) Grade 4 e 14 (11) Received t ocilizumab and/or s teroids 6 (5) T ocilizumab only 4 (3) Steroids only 4 (3) Tocilizumab and Steroids Overall maximum CRS grade and interventions
20 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Durability of IMA402 “ Pembrolizumab Across All Indications in Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 BOR, best overall response; BL, baseline; cCR , confirmed complete response; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease; sqNSCLC , squamous non - small cell lung cancer. Data cutoff Jun 1, 2026 Cutaneous melanoma Uveal melanoma Ovarian cancer Endometrial cancer sqNSCLC Synovial sarcoma BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing response/ disease control Ongoing treatment IMA402 + Pembrolizumab n= 40
21 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Responses to IMA402 “ Pembrolizumab in PRAME high Melanoma Prof. Dr. Dirk Schadendorf ; Abstract #8465 BOR, best overall response; BL, baseline; cCR , confirmed complete response; cORR , confirmed objective response rate; ICI, immune checkpoint inhibitor; PD, progressive disease; (c)PR, (confirmed) partial re spo nse; RP2D, recommended phase 2 dose; SD, stable disease. Data cutoff Jun 1, 2026 All patients with melanoma in the efficacy population received prior ICI (n=22) Melanoma IMA402 + Pembrolizumab (n=2) IMA402 Monotherapy (n=20) IMA402 ± Pembrolizumab (n=22) 1/2 30% (6/20) 32% (7/22) cORR BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing response/ disease control Ongoing treatment IMA402 monotherapy IMA402 + pembrolizumab
22 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. a iRECIST , developed by the RECIST Working Group, adapts RECIST 1.1 definition for progression for immunotherapies by introducing unco nfi rmed ( iUPD ) and confirmed ( iCPD ) progression to account for atypical response patterns. Patients with iUPD not confirmed at a subsequent scan but turning into SD or response are not considered progressive according to iRECIST . PFS (according to RECIST 1.1) and iPFS (according to iRECIST ), are prospectively defined co - secondary endpoints in the IMA402 trial protocol to provide a balanced view of efficacy. Ongoing patients were censored at the data cutoff for PFS, iPFS and OS; PFS, iPFS and OS rates were calculated using the Kaplan – Meier method. mFU , median follow up; mOS , median overall survival; mPFS , median progression - free survival; RP2D, recommended phase 2 dose; SD, stable disease. Promising Initial PFS and OS in PRAME high Melanoma (n=22) Prof. Dr. Dirk Schadendorf ; Abstract #8465 Data cutoff Jun 1, 2026 Median PFS Median iPFS a Median OS 3.1 18.2 mPFS (mo) mFU (mo) 34% 6mo - PFS rate 4.8 6.9 miPFS (mo) mFU (mo) 46% 6mo - iPFS rate Not reached 8.8 mOS (mo) mFU (mo) 91% 1y - OS rate Initial survival data indicate promising overall survival across all treatment outcomes 0 (14) 0 (14) 0 (14) 0 (14) 1 (13) 15 (0) <10mg, at risk (event) 0 (17) 1 (17) 2 (17) 3 (16) 7 (14) 22 (0) ≥ 10mg, at risk (event) 0 (14) 0 (14) 0 (14) 0 (14) 2 (12) 15 (0) 0 (13) 1 (13) 2 (13) 3 (13) 8 (11) 22(0) 0 (11) 1 (11) 3 (10) 8 (6) 12 (3) 15 (0) 0 (2) 1 (2) 2 (2) 7 (2) 15 (2) 22 (0) Within RP2D range ( ≥ 10 mg), n=22 Below RP2D range (<10 mg), n=15
23 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. PRAME Prevalences in Selected Indications Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Data on file: PRAME target prevalence is based on TCGA RNAseq analysis using proprietary mass spec - guided initial expression th reshold. TCGA, The Cancer Genome Atlas. Data cutoff Jun 1, 2026 PRAME negative PRAME low PRAME high PRAME positive PRAME high based on actual in - house data PRAME high TCGA PRAME positive TCGA a Indication >80% (n=136) 92% 95% Cutaneous melanoma 60% - 95% (n=15) 95% 97% Uterine carcinoma ~60% (n=50) 64% 84% Ovarian carcinoma
24 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Outlook: Liquid Biopsy for Patient Selection Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Non - responder: PD, SD. Responder: PR, cPR , cCR . # Mann - Whitney U test cCR , confirmed complete response; (c)PR, (confirmed) partial response; PD, progressive disease; SD, stable disease. Data cutoff Jun 1, 2026 • Proprietary liquid biopsy assay for patient selection • Few millilitres of blood sufficient • Fast, sensitive and reliable detection of PRAME in blood • Representative PRAME levels across all tumor lesions prior to treatment start Best Overall Response Efficacy Population IMA402 Monotherapy Only BOR (RECIST 1.1) PD SD PR cPR cCR n=36 Liquid biopsy assay score a a #
25 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Outlook: Decitabine as Potential PRAME Enhancer for Combination with IMA402 Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Data on file. SCC25: epithelial - like squamous cell carcinoma cell line. OVCAR3: Ovarian carcinoma cell line. CpC , copy number per tumor cell; EC50=n.d., half maximal effective concentration not determined; IFN, interferon Data cutoff Jun 1, 2026 Pharmacologic upregulation of PRAME Rationale: Based on literature • Increased PRAME expression and pHLA presentation • Induction of type I IFN • Leading to HLA upregulation and modulation of tumor microenvironment • Effects described in different indications Based on preclinical data a Median CpC Decitabine SCC25 OVCAR3 Median CpC Decitabine Decitabine increases PRAME copy numbers per cell SCC25 SCC25 Control + Decitabine high IMA402 IMA402 Decitabine enables PRAME targeted cytotoxicity through IMA402 Selected Publications Gutierrez - Cosío S, et al. Leuk Res . 2012;36(7)895 - 899 Gang AO, et al. Blood Cancer J . 2014;4(3):e197 Zhang W, et al. Oncotarget . 2016;7(29):45352 - 45369 Yao Y, et al. PLoS One. 2013;8(8):e70522 Topper MJ, et al. Cell . 2017;171(6):1284 - 1300 Goyal A, et al. Nat Commun . 2023;14(1):6731 Ortmann CA, et al. Ann Hematol . 2008;87(19):809 - 818 Stone ML, et al. Proc Natl Acad Sci U S A. 2017;114(51) Chiappinelli KB et al. Cell . 2015;162(5):974 – 986
26 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Clinical Responses in PRAME high Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Median target lesion sum of diameter. b Bridging therapy. BOR, best overall response; cCR , confirmed complete response; PFS, progression - free survival; cPR , confirmed partial response. Data cutoff Jun 1, 2026 Ongoing treatment PFS [months] BOR [max % change of target lesions] BOR (RECIST 1.1) Baseline tumor burden [cm] a Highest dose received [mg] List of prior treatment lines No of prior treatment lines Indication Yes 18.2 (ongoing) - 100 cCR 8.97 20 Nivolumab Ipilimumab + nivolumab Lenvatinib + pembrolizumab 3 Cutaneous melanoma No 8.4 - 100 cPR 2.2 21.5 Bevacizumab + chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, p egylated liposomal doxorubicin , mitoxantron) Chemotherapy (carboplatin, cisplatin) 3 Ovarian carcinoma Yes 13.8 - 84.3 cPR 7.0 30 Pembrolizumab Ipilimumab + nivolumab Chemotherapy (dacarbazine) Ipilimumab + nivolumab 4 Cutaneous melanoma Yes 5.1 - 77.3 cPR 4.4 30 Ipilimumab + nivolumab Lenvatinib + pembrolizumab 2 Cutaneous melanoma Yes 28.1 (ongoing) - 70 cPR 4.0 30 Ipilimumab + nivolumab Nivolumab Tebentafusp 3 Uveal melanoma Yes 6.7 (ongoing) - 68.4 cPR 9.6 12 Nivolumab Nivolumab Ipilimumab + nivolumab 3 Cutaneous melanoma Yes 6.9 (ongoing) - 65.2 cPR 10.0 10 + pembrolizumab Nivolumab Ipilimumab + nivolumab Nivolumab b Chemotherapy (dacarbazine) Pembrolizumab 5 Cutaneous melanoma Yes 3.5 (ongoing) - 60.4 cPR 13.5 45 Bevacizumab + niraparib + chemotherapy (carboplatin, paclitaxel) Mirvetuximab soravtansine 2 Ovarian carcinoma No 4.6 - 50.5 cPR 9.5 30 Bevacizumab + olaparib + chemotherapy (carboplatin, paclitaxel) Niraparib + chemotherapy (carboplatin, doxorubicin/caelyx) Chemotherapy (cisplatin, gemcitabine) 3 Ovarian carcinoma
27 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Clinical Responses in PRAME high Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Median target lesion sum of diameter. b Bridging therapy. BOR, best overall response; PFS, progression - free survival; (c)PR, (confirmed) partial response; SD, stable disease; T - VEC, talimogene laherparepvec ; TIL, tumor - infiltrating lymphocyte. Data cutoff Jun 1, 2026 Ongoing treatment PFS [months] BOR [max % change of target lesions] BOR (RECIST 1.1) Baseline tumor burden [cm] a Highest dose received [mg] List of prior treatment lines No of prior treatment lines Indication No 6.6 - 43.7 cPR 5.4 30 IFN  Nivolumab Ipilimumab + nivolumab 3 Cutaneous melanoma No 2.8 - 80.6 PR 3.1 30 Nivolumab Trametinib + dabrafenib Ipilimumab + nivolumab 3 Cutaneous melanoma No 1.4 (censored) - 21.7 SD 17.5 30 IFN  Ipilimumab + nivolumab Dabrafenib + trametinib Ipilimumab + nivolumab Chemotherapy ( darcabacin ) b Encorafenib + Binimetinib 6 Cutaneous melanoma No 4.8 - 16.8 SD 7.5 30 Nivolumab Ipilimumab + nivolumab Lenvatinib + pembrolizumab 3 Cutaneous melanoma Yes 3.1 - 10.6 SD 1.5 20 + pembrolizumab Pembrolizumab + T - VEC + IL2 1 Cutaneous melanoma No 10.2 - 9.5 SD 12.6 30 Pembrolizumab Ipilimumab + nivolumab TIL + Cy/Flu lymphodepletion 3 Cutaneous melanoma No 1.5 - 6.7 PD 6.0 12 Relatlimab + nivolumab Binimetinib + encorafenib Ipilimumab + nivolumab Dabrafenib + trametinib 4 Cutaneous melanoma No 4.6 0.8 SD 12.2 30 Pembrolizumab Ipilimumab + nivolumab Chemotherapy (darcabacin) 3 Cutaneous melanoma
28 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Clinical Responses in PRAME high Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Median target lesion sum of diameter. BOR, best overall response; PFS, progression - free survival; SD, stable disease; PD, progressive disease. Data cutoff Jun 1, 2026 Ongoing treatment PFS [months] BOR [max % change of target lesions] BOR (RECIST 1.1) Baseline tumor burden [cm] a Highest dose received [mg] List of prior treatment lines No of prior treatment lines Indication No 2.6 3.1 SD 9.7 30 Olaparib + megace + chemotherapy (carboplatin, paclitaxel) Chemotherapy (doxorubicin, carboplatin, paclitaxel) 2 Ovarian carcinoma No 4.7 3.5 SD 6.8 20 Olaratumab + chemotherapy (doxorubicin) Chemotherapy (paclitaxel, carboplatin) Pembrolizumab Trastuzumab – deruxtecan Chemotherapy (paclitaxel) 5 Endometrioid carcinoma No 2.6 3.6 SD 8.4 45 Talimogen - laherparepvec + nivolumab Ipilimumab + nivolumab + chemotherapy (bleomycin) Ipilimumab + nivolumab + daroumun Ipilimumab + nivolumab 4 Cutaneous melanoma No 2.4 5.7 SD 8.7 30 Pembrolizumab Ipilimumab + nivolumab IL2 Chemotherapy (dacarbazine) 4 Cutaneous melanoma No 1.6 17.1 SD 19.4 30 Nivolumab Ipilimumab + nivolumab 2 Cutaneous melanoma No 1.4 - 24.8 PD 13.7 12 Chemotherapy (doxorubicin, isosfamide) 1 Synovial sarcoma No 1.4 0 PD 2.1 20 Ipilimumab + nivoulamb Nivolumab IL2 + chemotherapy (cyclophosphamide, fludarabine) 3 Cutaneous melanoma No 1.4 9.4 PD 3.2 20 Chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, paclitaxel) Lenvatinib + pembrolizumab 3 Endometrioid carcinoma No 1.4 12.6 PD 9.5 30 Nivolumab Trametinib + dabrafenib Nivolumab Ipilimumab + nivolumab 4 Cutaneous melanoma
29 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Clinical Responses in PRAME high Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Median target lesion sum of diameter. BOR, best overall response; PFS, progression - free survival; SD, stable disease; PD, progressive disease. Data cutoff Jun 1, 2026 Ongoing treatment PFS [months] BOR [max % change of target lesions] BOR (RECIST 1.1) Baseline tumor burden [cm] a Highest dose received [mg] List of prior treatment lines No of prior treatment lines Indication No 1.4 20.8 PD 7.7 20 Durvalumab + bevacizumab + olaparib + chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, gemcitabine) Chemotherapy (carboplatin, p egylated liposomal doxorubicin ) Raludotatug + chemotherapy (paclitaxel) 4 Ovarian carcinoma No 0.7 23.8 PD 10.5 30 Bevacizumab + olaparib + chemotherapy (paclitaxel, carboplatin) Chemotherapy (carboplatin, p egylated liposomal doxorubicin ) Mirvetuximab - soravtansine 3 Ovarian carcinoma Yes 1.4 28.6 PD 11.2 30 Ipilimumab + nivolumab 1 Cutaneous melanoma No 1.4 34.8 PD 6.9 45 Encorafinib + binimetinib Ipilimumab + nivolumab Ipilimumab + nivolumab Encorafinib + binimetinib 4 Cutaneous melanoma No 1.4 41.1 PD 2.1 20 Pembrolizumab + IO102 - 103 Encorafenib + binimitinib 2 Cutaneous melanoma

----- dp255472_ex9903.htm -----
EX-99.3
4
dp255472_ex9903.htm
EXIBIT 99.3
Exhibit 99.3
Presented at ESMO Congress 2026 • October 23 - 27, 2026 • Madrid, Spain RESULTS • For all patients with melanoma, the median PFS was 6.1 months (range, 1.4 - 39.6+; Figure 3 ); median PFS for cutaneous melanoma was 6.0 months (1.4 - 39.6+) and for uveal melanoma was 8.5 months (1.4 - 32.9) 6 • The median OS was 16.2 months (range, 2.4 - 39.6+ months) 6 – 12 - month OS for all melanoma: 70%; cutaneous: 72%; uveal: 71% – 24 - month OS: 46%; cutaneous: 45%; uveal: 57% • The confirmed ORR was 56% (n=18/32) for all patients with melanoma (cCR=1; cPR=17) 6 – The median DoR was 14.6 months for all patients with melanoma (range, 4.2 - 38.2+ months); 6 of 18 (33%) responses were ongoing at data cutoff Figure 3. Time - to - Event Analyses 100 75 50 25 0 0 6 12 18 24 Time from Infusion (months) 30 36 42 PFS, % At Risk 33 Events 0 16 15 8 20 4 23 2 24 2 24 1 25 0 25 Median follow - up for PFS: 20.0 months 6 - month PFS: 55% 12 - month PFS: 37% • A total of 8 patients had PFS >12 months and 20 patients had PFS <12 months • Patients with PFS >12 months had a range of baseline and treatment characteristics ( Table 2 ) • In exploratory univariate Cox proportional hazards analyses, each clinical variable was evaluated separately. No variable showed a statistically significant association with PFS, as all 95% confidence intervals for the hazard ratios included 1 ( Figure 4 ) • Point estimates suggested longer PFS with lower LDH, a lower sum of target - lesion diameters, and a higher E:T ratio. – These findings are hypothesis - generating; the absence of statistical significance does not exclude clinically meaningful associations Table 2. Clinical Characteristics by PFS Category (>12 or <12 months) Patients Evaluable for PFS categorization a Baseline Characteristics PFS <12 Months (n=20) PFS >12 Months (n=8) All (N=33) 61 (37 - 79) 47 (31 - 71) 57 (31 - 79) Median age, years (range) 11 (55) 2 (25) 16 (48) Female, n (%) 11 (55) 6 (75) 20 (61) ECOG PS 0, n (%) 9 (45) 2 (25) 13 (39) ECOG PS 1, n (%) 2 (0 - 6) 3 (1 - 5) 2 (0 - 6) Median prior lines of systemic treatment (range) 1 (0 - 4) 1 (0 - 3) 1 (0 - 4) Median prior lines of ICI treatment (range) 18 (90) 6 (75) 27 (82) ≥1 line of ICI treatment, n (%) 11.9 (2.1 - 31.0) 10.1 (1.5 - 12.8) 10.4 (1.5 - 31.0) Median target lesion SLD, cm (range) 4.1 (1.1 - 13.8) 4.0 (1.5 - 6.6) 4.1 (1.1 - 13.8) Largest target lesion, cm (range) 12 (60) 5 (63) 19 (58) Elevated LDH at baseline, n (%) 1.11 (0.76 - 9.07) 1.02 (0.69 - 1.20) 1 (0.7 - 9.1) Median LDH п ULN (range) PFS <12 Months PFS >12 Months All Treatment Experience 3.52 (1.55 - 9.76) 6.16 (1.3 - 10.20) 4.04 (1.30 - 10.20) Median infused TCR T cell dose, п 10 9 (range) 0.038 (0.011 - 0.097) 0.071 (0.037 - 0.680) 0.0433 (0.0113 - 0.6800) Median effector cell to tumor burden ratio (range) b 5.6 (1.4 - 8.6) 20.7 (12.4 - 39.6+) 6.1 (1.4 - 39.6+) Median PFS, month (range) 11.4 (2.4 - 33.4+) NE (15.9 - 39.6+) 16.2 (2.4 - 39.6+) Median OS, month (range) 45 (9/20) 88 (7/8) 64 (21/33) ORR, % (n/N) 35 (7/20) 88 (7/8) 56 (18/32) cORR, % (n/N) a 5 patients were censored due to ongoing PFS <12 months (n=3) or withdrawal of consent (n=2). b Calculated by infused TCR T - cell dose divided by the sum of target lesions. Figure 4. Univariate Analysis of Clinical Characteristics and PFS Male vs female Higher E:T ratio a Fewer prior tx lines Trend for longer PFS Trend for shorter PFS Higher infused cell dose a No. of prior ICI lines Largest target lesion a Higher age at baseline Higher baseline LDH (fold ULN) a Baseline ECOG PS 1 vs 0 0.3 1.0 Hazard Ratio (95% CI) b Longer PFS Shorter PFS 3.0 Sum of target lesions a a Variables were log - transformed prior to modeling; Hazard ratios are reported per SD increase of the corresponding log - transformed variable. E:T ratio calculated by infused TCR T - cell dose divided by the sum of target lesions. b Hazard ratios are reported per 1 - SD (standard deviation) increase for all variables except ECOG PS (1 vs 0) and sex (male vs female). Interpreting the hazard ratios: HR >1 indicates a higher estimated hazard of disease progression or death; HR <1 indicates a lower estimated hazard; HR=1 indicates no difference. Each model evaluates one variable without adjustment for other variables. • The safety profile of anzu - cel was previously reported in detail. 4 The most common AEs were lymphodepletion - related cytopenias. CRS was early - onset (grade 1: 36%, grade 2: 46%, grade 3: 18%); ICANS (grade 1: 6%, grade 3: 6%) and HLH (grade 2: 3%, grade 3: 3%) were infrequent • This exploratory analysis provides temporal and clinical context for previously reported cytopenias, extending incidence reporting to characterize neutrophil recovery, supportive - care use, and clinical events during the later postinfusion period • Late N - ICAHT was observed in 8 of 33 patients (24%) including grade 3 - 4 N - ICAHT in 2 patients (6%; Table 3 ; Figure 5 ) • Growth factor support was used in 6 of 8 patients (75%) with N - ICAHT: 4/6 with grade 1 - 2 N - ICAHT and 2/2 with grade 3 - 4 N - ICAHT • One patient experienced pneumonia requiring hospitalization during the N - ICAHT period • Both grade 3 - 4 N - ICAHT events improved to grade ≤2 by day 78 postinfusion • All N - ICAHT events resolved at a median of 78 days postinfusion (range, 51 - 272) Table 3. Incidence and Grade of Late N - ICAHT All Melanoma Patients (N=33), n (%) Parameter 8 (24.2) Late N - ICAHT beyond day 28 a 2 (6.1) Grade 1 4 (12.1) Grade 2 1 (3.0) Grade 3 1 (3.0) Grade 4 a Late N - ICAHT grade was based on the second - lowest absolute neutrophil count between days 28 to 100 postinfusion and required ≥2 neutropenic measurements during this period, including ≥1 between days 35 – 60. Measurements before the day 28 visit were not used for late N - ICAHT grading but were considered when determining neutropenia onset and duration. Day 28 visits could have occurred up to 3 days before or after day 28. Figure 5. Late N - ICAHT Duration and Growth Factor Use п a b - 6 0 10 20 25 A - DL5 - 26 (UM) Patient A - DL5 - 24 (UM) A - DL5 - 34 (UM) A - DL4 - 07 (CM) A - DL5 - 28 (MM) A - DL5 - 32 (UM) A - DL5 - 14 (CM) A - DL5 - 10 (UM) 35 40 50 60 Days post IMA203 infusion 70 80 90 100 N - ICAHT (day 28 ц 3 days and beyond) Grade 1 Grade 2 Grade 3 Grade 4 Neutrophil measurement Grade 1 Grade 2 Grade 3 Grade 4 Normal ANC Growth factor (course) Ongoing at day 100 Growth factor (single dose) п End of study a Patient died from PD. b N - ICAHT remained without further worsening and resolved on day 272. N - ICAHT grades defined as grade 1 ≤1500 cells/µL; grade 2 ≤1000 cells/µL; grade 3 ≤500 cells/µL; grade 4 ≤100 cells/µL. ANC values were used for this analysis; grading is based on the 2nd lowest ANC value. Patients with at least 2 ANC values below thresholds between days 28 ( ц 3) to 100, with 1 abnormal ANC value occurring between days 35 - 60. ANC measurements before day 25 are displayed for context but are not used to define late N - ICAHT eligibility. Growth factor use shown as a diamond for a single - day dose or a line for a multi - day course (per - patient administration data). Poster 9049 Response Durability With Anzutresgene Autoleucel (Anzu - cel), a PRAME - directed T - cell Receptor T - cell Therapy, in Advanced Melanoma Winfried Alsdorf, 1 Diwakar Davar, 2 Sapna P. Patel, 3 Leonel Hernandez - Aya, 4 Tobias A.W. Holderried, 5 Antonia Busse, 6 Apostolia M. Tsimberidou, 7 Dejka M. Araujo, 7 Manik Chatterjee, 8 Silvana Hengler, 9 M. Alper Kursunel, 10 Delfi Krishna, 11 Dmitry Pankov, 11 Cedrik M. Britten, 9 Martin Wermke 12 1 Department of Hematology and Oncology University Hospital Hamburg Eppendorf, Hamburg, Germany; 2 University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center, Pittsburgh, PA, USA; 3 University of Colorado Cancer Center, Aurora, CO, USA; 4 University of Miami, Miami, FL , USA; 5 University Hospital Bonn, Bonn, Germany; 6 Charite Medical University Hospital, Berlin, Germany; 7 The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 8 Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; 9 Immatics Biotechnologies GmbH, Tübingen, Germany; 10 Immatics N.V., Tübingen, Germany; 11 Immatics US, Houston, TX, USA; 12 TU Dresden, Carl - Gustav - Carus Faculty of Medicine, NCT/UCC Early Clinical Trial Unit, Dresden, Germany CONCLUSIONS • Durable clinical benefit following anzu - cel for treatment of advanced melanoma was observed in patients with varied baseline and treatment characteristics 4 – No variable evaluated individually showed a statistically significant association with PFS – Point estimates suggested longer PFS with lower LDH, a lower sum of target - lesion diameters, and a higher E:T ratio; these findings remain hypothesis - generating and warrant further evaluation • Durable benefit was achieved with a one - time treatment and a time - limited treatment burden • Late N - ICAHT occurred in a minority of patients and resolved by data cutoff • These findings support continued postinfusion monitoring of complete blood counts in the subset of patients with incomplete hematologic recovery or recurrent cytopenias, with supportive care guided by clinical need and protocol recommendations BACKGROUND • For patients with advanced melanoma, treatment options after first - line therapy Figure 1. Anzu - cel Mechanism of Action anzu - cel (IMA203) PRAME - HLA - A*02:01 complex Tumor cell Intracellular PRAME Proteasome Peptides HLA - A*02:01 Other proteins Engineered PRAME - specific TCR provide limited responses and poor survival, highlighting the need for new systemic therapies with durable disease control 1 - 3 – 2 - year survival is approximately 40% in cutaneous melanoma following first - line immune checkpoint inhibitors and approximately 40% in previously treated uveal melanoma • TCR T - cell therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies 4 • Anzutresgene autoleucel (Anzu - cel, IMA203) is a one - time autologous TCR T - cell therapy targeting the cancer - associated antigen PRAME, which is expressed in >50 cancers and represents a novel immunotherapy target for melanoma ( Figure 1 ) 5 • Results from IMA203 - 101 (NCT03686124) demonstrate a predictable and manageable tolerability profile and rapid, deep, and durable systemic antitumor activity with anzu - cel 6 • Here we characterize durable clinical benefit, including baseline characteristics associated with extended PFS (>12 months), and provide a longitudinal assessment of hematologic recovery – In addition to conventional cytopenia reporting, immune effector cell - associated hematotoxicity (ICAHT) criteria, developed to characterize the depth and duration of neutropenia following CAR T - cell therapy, were applied to evaluate early and late hematotoxicity, supportive care requirements, and associated infectious complications METHODS • IMA203 - 101 (NCT03686124) is an ongoing phase 1 study evaluating anzu - cel in patients with PRAME - positive solid tumors ( Figure 2 ) • Data cutoff: Sept 24, 2025 (median follow - up for PFS: 20 months) • Univariate Cox proportional hazards regression models were used to evaluate a subset of clinical factors associated with PFS – The current presentation is a part of a broader exploratory analysis to examine variables across the patient journey including baseline characteristics, starting apheresis material, manufacturing, treatment, and postinfusion treatment course – This analysis was conducted in a cohort of patients with advanced melanoma who were treated with anzu - cel at cell doses between 1 - 10 billion TCR T cells (N=33); clinical variables evaluated in patients with melanoma with complete data included age, sex, ECOG performance status, target lesions, largest target lesion, LDH, prior lines of ICI therapy, infused cell dose, and effector - to - tumor (E:T) ratio – Variables were evaluated individually, without adjustment for other clinical or treatment characteristics – 5 patients were censored due to ongoing PFS <12 months (n=3) or withdrawal of consent (n=2) • Hematologic recovery was characterized using ANC measurements following anzu - cel one - time infusion • Late neutropenia - associated ICAHT (N - ICAHT) was assessed using EHA/EBMT consensus ANC thresholds developed for CAR T - cell therapy ( Table 1 ) 7,10 • For this analysis, late N - ICAHT required ≥2 ANC measurements meeting the applicable threshold between days 28 ( ц 3) to 100, including ≥1 qualifying ANC measurement between days 35 - 60 Table 1. Late N - ICAHT Grading ANC (cells/μL) Parameter, n (%) ≤1500 Grade 1 ≤1000 Grade 2 ≤500 Grade 3 ≤100 Grade 4 Figure 2. IMA203 - 101 study design Primary • Tolerability • Determination of RP2D Secondary • Anzu - cel T - cell engraftment, persistence • Efficacy • No active brain metastasis • Advanced (unresectable and/or metastatic) solid tumors • Age ≥18 years • ECOG PS 0 - 1 • HLA - A*02:01 positive • PRAME positive • No available SOC treatment options • Measurable disease (RECIST 1.1) • No active brain metastasis Screening/Manufacturing Treatment/Observation Follow - Up ≈2 - week turnaround time Manufacturing of anzu - cel HLA - A*02:01 testing (blood) Prevalence 8 : US: 41% EU: 48% PRAME testing Biopsy or archived tissue Lymphodepletion Fludarabine 30 mg/m 2 Cyclophosphamide 500 mg/m 2 Days - 6 to - 3 Low - dose IL - 2a 1M IU SUBQ Days 1 - 5; 1M IU SUBQ BID Days 6 - 10 (outpatient administration at investigator’s discretion) Leukapheresis Anzu - cel one - time infusion Day 0 KEY OBJECTIVES PATIENT JOURNEY KEY ELIGIBILITY CRITERIA ABBREVIATIONS: ANC, absolute neutrophil count; BID, twice daily; CAR, chimeric antigen receptor; cCR, confirmed complete response; cORR, confirmed objective response rate; cPR, confirmed partial response; CRS, cytokine release syndrome; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; E:T, effector cell to tumor burden ratio; FU, follow - up; HLA, human leukocyte antigen; HLH, hemophagocytic lymphohistiocytosis; ICAHT, immune effector cell - associated hematotoxicity; ICANS, immune effector cell - associated neurotoxicity syndrome; ICI, immune checkpoint inhibitor; IL, interleukin; IU, international unit; LDH, lactate dehydrogenase; N - ICAHT, neutropenia - associated ICAHT; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression - free survival; PRAME, preferentially expressed antigen in melanoma; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; RP2D, recommended phase 2 dose; SD, standard deviation; SLD, sum of the longest diameters; SOC, standard of care; SUBQ, subcutaneous; TCR, T - cell receptor; ULN, upper limit of normal. Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without written permission of the authors. ACKNOWLEDGMENTS • We thank the patients, their families, and their caregivers for participating in this study • We thank the study investigators, site personnel, and independent data monitoring committee • This study was funded by Immatics, Inc • Biostatistical support was provided by Haneen Aldehayat, MSc, and Dina Cramer, PhD, of Immatics, Inc. • Medical writing support was provided by Decera Clinical, funded by Immatics, Inc • Tobias A.W. Holderried is currently affiliated with the Medical University of Graz in Graz, Austria REFERENCES: 1. Ascierto PA, et al. J Clin Oncol . 2023;15(41):2724 - 2735. 2. VanderWalde A, et al. Nat Med . 2023;29(9):2278 - 2285. 6. Davar D, et al. ASCO 2026. Abstract #9508. 7. Rejeski K, et al. Blood . 2023;142:865 - 877. 3. Sacco JJ, et al. J ImmunoTher Cancer . 2024;12:e009028. 8. Gragert L, et al. Hum Immunol . 2013;74:1313 - 1320. 4. Klebanoff CA, et al. Nat Rev Drug Discov . 2023;22(12):996 - 1017. 9. Rejeski K, et al. Blood Adv . 2024;8:1857 - 1868. 5. Wermke M, et al. Nat Med . 2025;31(7):2365 - 2374. 10. Rejeski K, et al. Blood . 2023; 142(10):865 - 877. DISCLOSURES: WA: Travel grants: Janssen, Immatics and BioNTech; Honoraria: GSK, Astellas, Janssen, and AstraZeneca; Research funding: Affimed and BioNTech.

----- dp255472_ex9904.htm -----
EX-99.4
5
dp255472_ex9904.htm
EXHIBIT 99.4
Exhibit 99.4
© Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation October 24, 2026
Forward - Looking Statement 2 No Offer or Solicitation . This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction . No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933 , as amended, or in an offering exempt from registration . Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company’s own internal estimates and research . In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions . Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source . All the scientific and clinical data presented within this presentation are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification . This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their respective control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation . Forward - Looking Statements . Certain statements in this presentation may be considered forward - looking statements . Forward - looking statements generally relate to future events or the Company’s future financial or operating performance . For example, statements concerning timing of data read - outs, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration - enabling), the timing and outcomes of IND, CTA, BLA and other regulatory filings, the timing of commercial launches, estimated market opportunities, manufacturing timetables, capacity and success rates, the potential benefits of product candidates, the Company’s intended strategy, and other metrics are forward - looking statements . In some cases, you can identify forward - looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology . Such forward - looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements . These forward - looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain . New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties . Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20 - F and other filings with the Securities and Exchange Commission (SEC) . Nothing in this presentation should be regarded as a representation by any person that the forward - looking statements set forth herein will be achieved or that any of the contemplated results of such forward - looking statements will be achieved . You should not place undue reliance on forward - looking statements, which speak only as of the date they are made . The Company undertakes no duty to update these forward - looking statements .
PRAME prevalence in selected indications PRAME Is Expressed in More Than 50 Cancers Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a Data on file: PRAME target prevalence is based on a proprietary initial mass spec - guided expression threshold applied to RNAseq and/or IHC data (approximate values, values between 95 - 100% shown as 95%); anzu - cel (IMA203), IMA203CD8, IMA402 are being evaluated in separate clinical trials ; NSCLC: Non - small cell lung cancer ≥95 % ≥10 % % PRAME+ patients a Indication 95% Cutaneous Melanoma 95% Uterine Carcinoma 95% Uterine Carcinosarcoma 95% Synovial Sarcoma 90% Uveal Melanoma 90% Mucosal Melanoma 85% Ovarian Carcinoma Subtypes 70% Squamous Cell NSCLC 65% Triple - negative Breast Carcinoma 45% Small Cell Lung Cancer 45% Esophageal Carcinoma Subtype 40% Kidney Carcinoma Subtype 35% Cholangiocarcinoma 30% HER2 - Enriched Breast Carcinoma 25% Adenocarcinoma NSCLC 25% Head & Neck Squamous Cell Carcinoma 20% Hepatocellular Carcinoma 20% Bladder Carcinoma 3 PRAME Indication Cutaneous Melanoma Endometrioid Endometrial Carcinoma Uterine Carcinosarcoma Synovial Sarcoma Acral Melanoma Uveal Melanoma Mucosal Melanoma Endometrial Clear Cell Carcinoma Endometrial Serous Carcinoma Ovarian Serous Cystadenocarcinoma Ovarian Clear Cell Carcinoma Ovarian Endometrioid Carcinoma Head and Neck Salivary Duct Carcinoma Adenoid Cystic Carcinoma Neuroblastoma Malignant Rhabdoid Tumor Wilms Tumor (Nephroblastoma) Squamous Cell NSCLC Triple Negative Breast Carcinoma (TNBC) Cervical Adenosquamous Cell Carcinoma Large Cell Neuroendocrine Lung Carcinoma (LCNEC) Basal Cell Carcinoma Mucoepidermoid Carcinoma Large Cell Lung Carcinoma (LCLC) Spindle Cell Melanoma Testicular Germ Cell Tumor (Seminoma and Non - Seminoma) Myxoid Liposarcoma Angiosarcoma Small Cell Lung Cancer (SCLC) Esophageal Small Cell Carcinoma Cutaneous Squamous Cell Carcinoma Thymoma Merkel Cell Carcinoma Endometrial Sarcoma Esophageal Squamous Carcinoma Esophageal Adenosquamous Carcinoma Kidney Renal Papillary Cell Carcinoma Malignant Peripheral Nerve Sheath Tumor (MPNST) Cholangiocarcinoma Cervical Adenocarcinoma Head and Neck Salivary Gland Carcinoma Osteosarcoma HER2 - Enriched Breast Carcinoma Embryonal Rhabdomyosarcoma Adenosquamous NSCLC Diffuse Large B - cell Lymphoma (DLBCL) Sarcomatoid Carcinoma of the Lung Adenocarcinoma NSCLC Head and Neck Squamous Cell Carcinoma (HNSCC) Alveolar Rhabdomyosarcoma Ovarian Mucinous Carcinoma Adrenocortical Carcinoma Kidney Renal Clear Cell Carcinoma Hepatocellular Carcinoma Bladder Urothelial Carcinoma Cervical Squamous Cell Carcinoma Non - Squamous Anal Carcinoma Pancreatic Neuroendocrine Adenocarcinoma Prostate Neuroendocrine Adenocarcinoma Liposarcoma Undifferentiated Pleomorphic Sarcoma Acute Myeloid Leukemia (AML) Ewing Sarcoma Ovarian Leiomyosarcoma Breast Carcinoma, Luminal A Breast Carcinoma, Luminal B Squamous Anal Carcinoma Stomach Adenocarcinoma Esophageal Adenocarcinoma Fibrosarcoma Anaplastic Thyroid Carcinoma (…) Cancer Cell Death IMA402 PRAME Bispecific a nzu - cel (IMA203) PRAME Cell Therapy IMA203CD8 PRAME Cell Therapy Immatics Is the Global Leader in Precision Targeting of PRAME with 3 clinical product candidates
Immatics Is the Global Leader in Precision Targeting of PRAME • P RAME is an intracellular protein pre sented as a peptide on the surface of tumor cells by HLA molecules 1 • The PRAME peptide can be targeted by T - cell receptors (TCRs) engineered by Immatics, thus overcoming limitations of classical antibodies and CAR T - cell therapies not able to access intracellular targets 1,2 • PRAME has multiple functions in tumor biology enhancing tumor cell survival, tumor proliferation and resistance to apoptosis a , 3,4 • PRAME expression has been associated with poor prognosis incl. shorter survival 5,6,7,8 • PRAME is homogenously expressed in tumor tissue 9 4 PRAME RNA detection in tumor samples (ISH) Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a Activation of proliferative and survival pathways , including PI3K/AKT/mTOR 3 , and i nhibition of retinoic acid signaling preventing retinoic acid - induced differentiation and apoptosis 4 1 Wermke et al., 2025; 2 Chandran et al., 2019, 3 Yu et al., 2023; 4 Epping et al., 2005; 5 Al - Khadairi & Decock . 2019; 6 Naik et al., 2021 ; 7 Gezgin et al., 2017; 8 Field et al., 2016; 9 Hukelmann et al., SITC 2022. PRAME anzu - cel (IMA203) s qNSCLC Ovarian Cancer
Target Indication Modality Product candidate 2L advanced melanoma Cell therapy Anzu - cel (IMA203) Uveal melanoma Cell therapy Anzu - cel (IMA203) Solid cancers Cell therapy Anzu - cel (IMA203) + mRNA - 4203 Gynecologic cancers Cell therapy IMA203CD8 Other so lid cancers Melanoma, gynecologic cancers, others Bispecific IMA402 Melanoma, gynecologic cancers, others Bispecific IMA402 + ICI a sqNSCLC Bispecific IMA402 + IMA401 MAGEA4/8 HNSCC, sqNSCLC, others Bispecific IMA401 ± ICI other Undisclosed Bispecific Undisclosed b Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities 5 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a In combination with immune checkpoint inhibitor (pembrolizumab or nivolumab/ re latlimab ); b mRNA - enabled in vivo expressed TCER® molecules ; c Phase 1a: Dose escalation, Phase 1b: Dose expansion ; HNSCC , head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor; sqNSCLC , squamous non - small - cell lung cancer PRAME PRAME PRAME PRAME PRAME PRAME PRAME PRAME PRAME / MAGEA4/8 SUPRAME Preclinical 1a 1b 2 3 Phase c 3 PRAME product candidates 2 Therapeutic modalities 3 PRAME combinations
Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities 6 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), All patient numbers refer to PRAME+/HLA - A*02:01+ patients in the US and EU5; Source: Internal Forecast 2 026; EU5: France, Germany, Italy, Spain, United Kingdom; ICI, Immune checkpoint inhibitor; SOC, standard of care; sqNSCLC , squamous non - small - cell lung cancer PRAME Anzu - cel (IMA203) PRAME Cell Therapy 1 PRAME WAVE 1 Market entry in advanced melanoma ~10K addressable patients p.a. • Anzu - cel is expected to be Immatics’ first PRAME therapy to enter the market • First target indications: 2L unresectable or metastatic melanoma; metastatic uveal melanoma • Enhanced pharmacology provides potential to expand to tumor - agnostic label in 2L PRAME solid cancers beyond melanoma , including ovarian cancer, endometrial cancer IMA203CD8 PRAME Cell Therapy Expansion to all advanced PRAME cancers >75K addressable patients p.a. 2 PRAME WAVE 2 • Next - gen half - life extended bispecific as monotherapy or ICI/SOC combo in earlier and later treatment lines • First target indications: melanoma, gynecologic cancers, sqNSCLC (IMA402/ IMA401 combination ) IMA402 PRAME Bispecific Expansion to earlier - line PRAME cancers >145K addressable patients p.a. 3 PRAME WAVE 3 >230K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 p.a.
Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities 7 PRAME Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a Includes all benefits of Breakthrough Therapy Designation; b Pre - specified final analysis expected to be triggered upon the occurrence of a defined number of events for PFS (progressive disease or death) ; c B eing conducted at Hopp Children's Cancer Center Heidelberg ( KiTZ ), Germany; ICI , immune checkpoint inhibitor; IIT, investigator - initiated trial; sqNSCLC , squamous non - small - cell lung cancer STATUS EXPECTED MILESTONES □ Ph1a data update with focus on ovarian cancer at relevant doses at a major medical conference: ASCO 2026 □ Ph1a dose escalation completed: 2026 □ Updated data across multiple PRAME - positive tumors: ESMO 2026 □ Completion of uterine cancer cohort: 1H 2027 □ Start of pediatric Phase 1/2 IIT c : 1H 2027 IMA203CD8 PRAME Cell Therapy • PRAME cell therapy leveraging CD8 and CD4 T cells • Enhanced pharmacology • Phase 1 study ongoing 2 PRAME WAVE 2 x x □ Initiation of addtl . Ph1b/Ph2 expansion cohorts in melanoma and gyn - onc : 2026 □ Initiation of IMA402/IMA401 combo in sqNSCLC : 2026 □ Ph1b data update at RP2D range: ESMO 2026 □ First data on combination cohorts incl. IMA402/IMA401 in sqNSCLC : 2027 IMA402 PRAME Bispecific • Off - the - shelf Bispecific • Next - gen, half - life extended format • Phase 1b dose expansion ongoing 3 PRAME WAVE 3 x x □ Data update from Ph1/2 trial in unresectable or metastatic melanoma and metastatic uveal melanoma: ASCO 2026 □ Ph3 SUPRAME disclosure of topline data for final analysis b : 1H 2027 □ BLA submission: 2027 Anzu - cel (IMA203) PRAME Cell Therapy • Orphan Drug and RMAT designation a by FDA • Phase 3 SUPRAME trial in patients with advanced melanoma post PD - 1 inhibitor ongoing; Primary endpoint: PFS • Phase 2 cohort in patients with metastatic uveal melanoma ongoing 1 PRAME WAVE 1 x >230K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 p.a.
Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities 8 PRAME a Target product profile (TPP) in monotherapy in 2L or later settings post SOC at recommended phase 2 dose (“RP2D”) for develop me nt beyond Ph1b. Other factors such as mPFS (median progression free survival) and mOS (median overall survival) may also be considered. SOC, standard of care Half - life extended (HLE) bispecific T cell engager (TCER®) Modality: Repeat dose Application : Primarily in earlier lines incl. frontline or (neo)adjuvant setting (in combination with SOC) Positioning: Outpatient administration, hospitals and community centers Deployment : ≥20% cORR , ≥6 months mDOR (monotherapy, 2L or later) TPP at RP2D a : Autologous TCR T - cell Therapy Modality: Single dose (“one and done”) (no tumor surgery, no high - dose IL - 2) Application: Primarily second line and later monotherapy setting Positioning: Administered in specialized hospitals and medical centers; potential for outpatient administration Deployment: ≥40% cORR , ≥6 months mDOR (monotherapy, 2L or later) TPP at RP2D a : LYMPHODEPLETION & INFUSION Tumor cell HLA PRAME peptide ADMINISTRATION TO PATIENT LEUKAPHERESIS GENETIC ENGINEERING & EXPANSION TCER® PRODUCTION “OFF - THE - SHELF” PRODUCT Cell Therapy TCER® PRAME Cell Therapy PRAME Bispecific
PRAME WAVE 1 Anzu - cel (IMA203) PRAME Cell Therapy Market Entry in Advanced Melanoma
Anzu - cel (IMA203) Opportunity Anzu - cel (IMA203) PRAME Cell Therapy: Market Entry in Advanced Melanoma 10 2L unresectable or metastatic melanoma ~10K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), All patient numbers refer to PRAME+/HLA - A*02:01+ patients in the US (~4,500) and EU5 (~5,500) in 2028; S ource: Internal Forecast 2026; EU5: France, Germany, Italy, Spain, United Kingdom PRAME Wave 1: anzu - cel ANZU - CEL (IMA203)
Positive Data and High Unmet Need 11 SUPRAME: Phase 3 randomized trial of anzu - cel vs. investigator choice in 2L advanced melanoma d ongoing (#NCT06743126) Phase 2 single arm cohort of anzu - cel in metastatic uveal melanoma ongoing (#NCT03686124) Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a Manufacturing success rate for Phase 1; b PRAME + /HLA - A*02:01 + addressable patient population, Source: Internal Forecast 2026; c Includes all benefits of Breakthrough Therapy Designation, RMAT designation received in multiple PRAME expressing cancers, including cutaneous and uve al melanoma; d 2L: patients with unresectable or metastatic melanoma who have received at least 1 prior PD - 1 inhibitor ; CRS: cytokine release syndrome; ICANS: immune effector cell associated neurotoxicity syndrome; cORR : confirmed objective response rate; mDOR : median duration of response; mPFS : median progression - free survival; OS: overall survival ; mFU : median follow - up; EU5: France, Germany, Italy, Spain, United Kingdom; Summary: Anzu - cel (IMA203) PRAME Cell Therapy in Advanced Melanoma Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave 1: anzu - cel • Anticipated & manageable cytopenias associated with lymphodepletion • Mostly mild to moderate CRS • Infrequent ICANS • Potential for outpatient administration Expected and Manageable Tolerability • cORR : 56% (18/32) • 42% (14/33) of patients had deep responses (≥50% tumor size reduction) • Encouraging activity in both cutaneous melanoma ( cORR 50%) and uveal melanoma ( cORR 67%) Compelling Response Rate • 14.6 months mDOR and ongoing responses for up to >3 years • mPFS of 6.1 months • mPFS 15.9 months in patients with deep responses • m OS : 16.2 months Durable Responses • Fast turnaround time: 7 - 8 days + 7 days QC release testing • 95% manufacturing success rate to reach target dose a • Optimized process to achieve desirable cellular functionality Rapid & Robust Manufacturing • ∼ 10K b addressable patients in US/EU5 in 2L advanced melanoma • Orphan Drug Designation and RMAT designation c received for the treatment of both, cutaneous and uveal melanoma Commercial Opportunity
Ph 1b Study of Anzu - cel (IMA203) PRAME Cell Therapy in Advanced Melanoma Patient Journey 12 HLA - A*02:01 Testing Blood sample Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Anzu - cel (IMA203) One - time infusion Lymphodepletion b Low dose IL - 2 c Safety and efficacy monitoring for 12 months Leukapheresis as source for cell product Process time of ~ 2 weeks 7 - 8 - day manufacturing process applying CD8/CD4 T cell selection 7 - day QC release testing PRAME testing in Phase 1 Due to high prevalence, PRAME testing no longer required in SUPRAME trial for cut. melanoma and Phase 2 cohort in uveal melanoma Prevalence a : US: 41%, EU: 48% PRAME Wave 1: anzu - cel Inclusion by HLA testing only – no PRAME testing required Standard leukapheresis for product manufacturing – no need for tumor biopsy or surgery Fast turn - around - time (~2 weeks) and manufacturing success rate of 95% d Expected and manageable tolerability profile with potential outpatient administration – no high - dose IL - 2 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a Gragert et al. 2013 and census numbers; HLA - A*02:01 prevalence in Immatics’ clinical trials: US 65% and Germany 55% as of March 2025; b 30 mg/m 2 Flu darabine and 500 mg/m 2 Cy clophosphamide for 4 days; c 1m IU SC daily days 1 - 5 and twice daily SC days 6 - 10, total dose is approx. only 5% of the overall dose for high - dose IL - 2 given typically with TIL therapy (Sarnaik et al. 2021 Journal of Clinical Oncology); d Manufacturing success rate for Phase 1
Patients with Metastatic Melanoma in High Unmet Need Settings: PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 13 a Mucosal melanoma n=2; melanoma of unknown primary n=1. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhib ito r; LDH, lactate dehydrogenase; TCR, T - cell receptor; ULN, upper limit of normal. Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave 1: anzu - cel Other Melanoma a n=3 Uveal Melanoma n=16 Cutaneous Melanoma n=14 All Melanoma n=33 Baseline Characteristics 51 (40, 58) 62 (32, 74) 55 (31, 79) 57 (31, 79) Age, median (range) 100 63 21 48 Female, % 33 44 36 39 Baseline ECOG status 1, % 2 (1, 3) 2 (0, 6) 2.5 (1, 5) 2 (0, 6) Prior lines of systemic treatment, median ( range) 2 (1, 2) 1 (0, 4) 2 (1, 3) 1 (0, 4) Prior ICI treatment, median (range) 100 (3/3) 63 (10/16) 100 (14/14) 82 (27/33) ≥1 line of ICI treatment, % (n/N) — 63 (10/16) — — Prior tebentafusp , % (n/N) 8.7 (2.1, 17) 10.3 (3.1, 21) 12.1 (1.5, 31) 10.4 (1.5, 31) Tumor burden Target lesion SLD, cm, median (range) 17 (5, 20) 7 (3, 13) 6 (1, 10) 6 (1, 20) Target + non - target lesions, n, median (range) 67 94 64 79 Liver metastasis, % 33 0 0 3 Brain metastasis, % 100 50 71 64 Lung metastasis, % 13 (81) Uveal melanoma: Liver + extrahepatic, n (%) 2 (13) / 1 (6) Liver only / extrahepatic only, n (%) 33 0.9 (0.8, 1.6) 56 1.1 (0.7, 9.1) 64 1.1 (0.7, 9) 58 1 (0.7, 9.1) Elevated LDH at baseline, % LDH  ULN, median, (range) Other Melanoma Uveal Melanoma Cutaneous Melanoma All Melanoma Treatment Experience 3.33 (1.73, 7.94) 3.94 (1.62, 8.43) 4.58 (1.30, 10.20) 4.04 (1.30, 10.20) Infused TCR T cell dose (  10 9 ), median (range)
Anzu - cel (IMA203) PRAME Cell Therapy Demonstrated an Expected and Manageable Tolerability Profile 14 All Melanoma ( n =33) TEAEs in ≥30% Grade ≥3 Any grade Preferred term, n (%) 0 22 (67) Nausea 6 (18) 17 (52) ALT/AST increased 3 (9) 14 (42) Rash a 0 13 (39) Fatigue 0 12 (36) Constipation 3 (9) 10 (30) Hyponatremia 0 10 (30) Pyrexia All Melanoma (n=33) AESI Grade ≥3 Any grade Preferred term, n (%) 6 (18) 33 (100) CRS 2 (6) 4 (12) ICANS 1 (3) 2 (6) HLH All Melanoma (n=33) Key Lab Abnormalities Grade ≥3 Any grade Preferred term, n (%) 33 (100) 33 (100) Any cytopenia 33 (100) 33 (100) Neutropenia 17 (52) 33 (100) Anemia 13 (39) 31 (94) Thrombocytopenia 3 3 (100) 33 (100) Leukopenia 33 (100) 33 (100) Lymphopenia a Includes rash and rash maculopapular . Grades were determined according to NCI - CTCAE v 5 . 0 . Grades for CRS and ICANS were determined according to CARTOX criteria ( Neelapu et al, 2018 , for patients enrolled under protocol v 11 . 0 and higher according to Neelapu et al . 2019 ) . All TEAEs regardless of relatedness to study treatment are presented . System Organ Class Blood and lymphatic system disorders excluded from analysis ; Adverse events are coded to Preferred Term (PT) according to the MedDRA v 24 . 0 . Patients are only counted once per preferred term by the highest severity grade reported in the EDC . AESI, adverse event of special interest ; ALT, alanine aminotransferase ; AST, aspartate aminotransferase ; CRS, cytokine release syndrome ; d, day ; HLH, haemophagocytic lymphohistiocytosis ; ICANS, immune effector cell - associated neurotoxicity syndrome ; mo , month ; TEAE, treatment - emergent adverse event . Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave 1: anzu - cel Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion • Most grade ≥3 cytopenias (any lineage) resolved to grade 2 or better within 30 days of lymphodepletion Immune - mediated AESIs occurred by Day 30 of TCR T - cell infusion • Expected and manageable CRS, mostly grade 1/2, consistent with mechanism of action • Infrequent, manageable, and mostly mild ICANS
Anzu - cel (IMA203) PRAME Cell Therapy Induced Rapid and Deep Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 15 Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave 1: anzu - cel n=33 n=3 n=16 n=14 5 6 % (18/3 2 ) 1/3 6 7 % (10/15) 5 0 % (7/1 4 ) cORR b 6 4 % (21/33) 2/3 6 9 % (11/16) 57% (8/14) ORR 91% (30/33) 3/3 8 8 % (14/16) 9 3 % (13/14) DCR Cutaneous Melanoma Uveal Melanoma Melanoma (other) a All Melanoma • Median time to BOR was 1.4 months (1.2 - 2.8) • Most responders exhibit shrinkage of ≥1 lesion by first scan • Responses observed in target and non - target lesions BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing a Includes melanoma (other) n=3: MM n=2, MUP n=1; b Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfir med PR/CR were excluded. c Patient left study (withdrew consent) with ongoing unconfirmed PR.* Maximum change of target lesions and RECIST1.1 response a t different timepoints. Anzu - cel, a nzutresgene autoleucel; BOR, best overall response; cCR , confirmed complete response; cORR , confirmed objective response rate; cPR , confirmed partial response; DCR, disease control rate at week 6; PD, progressive disease; PR, partial response; RECIST, Res pon se Evaluation Criteria in Solid Tumors; SD, stable disease.
Change in Sum of Longest Diameter of Target Lesions from Baseline [%] Months Post T - cell Infusion Ongoing response at 39.6 mo Response until 32.9 mo BL PR cCR cPR PR SD PD Ongoing Anzu - cel (IMA203) PRAME Cell Therapy Induced Durable Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 16 Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave 1: anzu - cel a Includes melanoma (other) n=3: mucosal melanoma n=2, melanoma of unknown primary n=1. Anzu - cel, a nzutresgene autoleucel; BL, baseline; cCR , confirmed complete response; cPR , confirmed partial response; mDOR , median duration of response; mFU , median follow - up; mo , month; ND, not defined; PD, progressive disease; PR partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease. All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 14.6 (4.2, 38.2+) 11 (4.4, 31.6) 17.9 (4.2, 38.2+) mDOR [ mo ] (range) 18.7 ND 18.7 mFU [ mo ]
Anzu - cel (IMA203) PRAME Cell Therapy Induced Durable Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 17 Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave 1: anzu - cel Median Progression Free Survival Median Overall Survival All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 6.1 (1.4, 39.6+) 20.0 8.5 (1.4, 32.9) 10.4 6.0 (1.4 , 39.6+) 20.0 mPFS [ mo ] (range) mFU [ mo ] All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 16.2 (2.4, 39.6+) 17.3 NR (4.5, 34.2) 14.3 1 3 .9 (2.4, 39.6+) 20.0 mOS [ mo ] (range) mFU [ mo ] 6 - month PFS rate: 55% 100 PFS [%] 0 75 50 25 0 6 12 18 24 30 36 42 Time from Infusion [months] 33 16 8 4 2 2 1 0 0 15 20 23 24 24 25 25 At Risk Events PFS for All Melanoma Indications (n=33) 12 - month PFS rate: 37% 24 - month OS: 46% 100 OS [%] 0 75 50 25 0 6 12 18 24 30 36 42 Time from Infusion [months] 33 29 17 7 3 3 1 0 0 2 9 14 14 14 14 14 At Risk Events OS for All Melanoma Indications (n=33) 12 - month OS: 70% a Includes melanoma (other) n=3: mucosal melanoma n=2, melanoma of unknown primary n=1; PFS and OS of ongoing patients censored a t data - cut; PFS and OS rates were calculated using Kaplan - Meier method. Anzu - cel, a nzutresgene autoleucel; mFU , median follow - up; mOS , median overall survival; mPFS , median progression - free survival; OS, overall survival; PFS, progression - free survival.
These data are derived from different clinical trials at different points in time with differences in trial design and patien t p opulations. As a result, cross - trial comparisons cannot be made, and no head - to - head clinical trials have been conducted. Anzu - cel (IMA203) PRAME Cell Therapy in Melanoma: Overview of Competitive Studies PFS and OS Data in Melanoma Cohorts mOS (months) mPFS (months) Prior lines of therapies M elanoma patient population N Phase Drug Product 16.2 6.1 3% n=0, 24% n=1, 30% n=2, 24% n=3, 6% n=4, 6% n=5, 6% n=6 82% received prior ICI (median of 1 prior line of ICI in overall population, median of 2 prior lines of ICI in cut. melanoma) Median of 2 prior lines, median of 2.5 prior lines in cut. melanoma 42% cutaneous 48% uveal 9% other 33 1b (Dose Expansion) Anzu - cel in Melanoma 6.3 2.6 0% n=1, 27% n=2, 73% n>2 prior lines 100% received prior ICI (median of 2 prior lines of ICI, median of 2.5 prior lines of ICI in cut. melanoma) Median of 4 prior lines, median of 4.5 prior lines in cut. melanoma 73% cutaneous 18% uveal 9% other 11 1a (Dose Escalation) Anzu - cel in Melanoma 5.3 2.5 0% n=1, 16% n=2, 84% n>2 prior lines 100% received prior ICI (median 3 prior lines of ICI) Median of 4 prior lines, median of 4.5 prior lines in cut. melanoma 63% cutaneous 11% uveal 26% other 19 1a (Dose Escalation) IMA201/202/ anzu - cel combined in Melanoma 13.9 4.1 median of 3 prior lines (min/max: 1/9) 100% received prior ICI 54% cutaneous 0% uveal 45% other 153 Registrational Ph2 Lifileucel (C - 144 - 01, Cohort 2+4) 1 11.6 2.9 57% n=1, 27% n=2, 12% n>2 prior lines 99% received prior ICI 85% cutaneous 0% uveal 15% other 238 3 Tilsotolimod + Ipilimumab (ILLUMINATE - 301) 2 14.7 2.1 46% n=1, 35% n=2, 19% n≥3 prior lines 99% received prior ICI 68% cutaneous 0% uveal 32% other 354 1/2 Nivolumab + Relatlimab (RELATIVITY - 020, D1 Cohort) 3 32.2 3.6 100% received prior ICI 100% cutaneous 140 Registrational Ph2 Tudriqev (RP1) + Nivolumab (IGNYTE) 4 18 Data cutoff Sep 24, 2025 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), 1 Chesney et al., 2022; 2 Diab et al., 2024; 3 Ascierto et al., 2023; 4 Wong et al. 2025, Wong et al. 2026 ; PFS: progression - free survival; OS: overall survival; ICI: immune checkpoint inhibitor PRAME Wave 1: anzu - cel
Anzu - cel (IMA203) PRAME Cell Therapy Enhanced mPFS of >1 Year in Melanoma Patients with Deep Responses 19 Data cutoff Sep 24, 2025 Log - rank: 0.006 Anzutresgene autoleucel (anzu - cel, formerly IMA203), b, billion; ND, not defined; mFU , median follow - up; mPFS , median progression - free survival. PRAME Wave 1: anzu - cel Median dose 0.59b Median dose 3.33b Median dose 5.87b • 42% (14/33) patients in dose expansion have a deep response ( ≥ 50% tumor reduction) • This subgroup of patients has highly medically meaningful mPFS of more than 1 year • Patients with <50% tumor reduction (including tumor size increase) still observe a more than 2x longer mPFS as compared to patients treated in dose escalation with suboptimal doses mFU mPFS n ND 2.6 11 Dose Escalation anzu - cel 17.3 5.8 19 Dose Expansion anzu - cel <50% tumor size reduction (including tumor size increase) 39.6 15.9 14 Dose Expansion anzu - cel ≥50% tumor size reduction
TRIAL DESIGN Expected SUPRAME Trial Analyses SUPRAME: A Randomized Ph3 Trial of Anzu - cel (IMA203) PRAME - directed TCR T - cell Therapy vs Investigator’s Choice in Unresectable or Metastatic Melanoma post ICI Actively Enrolling across North America and Europe 20 Anzutresgene autoleucel ( anzu - cel, formerly IMA203) 1 Pre - specified final analysis will be triggered upon the occurrence of a defined number of events for primary endpoint PFS (prog ressive disease or death) statistically powered at 90%; ICI: immune checkpoint inhibitor; PFS: progression - free survival; ORR: objective response rate; TESAEs: treatment - emergent serious adverse events; AE: adverse eve nt; EORTC: European Organization for Research and Treatment of Cancer ; QLQ - C30: Core Quality of Life questionnaire; EQ - 5D - 5L: European Quality of Life 5 Dimensions 5 Level Version PRAME Wave 1: anzu - cel 1:1 Randomization PATIENT POPULATION: Unresectable or metastatic melanoma post ICI N=360 plus N=90 patients for increased OS power Anzu - cel (IMA203) Investigator’s choice nivolumab/ relatlimab , nivolumab, ipilimumab, pembrolizumab, lifileucel , chemotherapy PRIMARY Progression - free survival ENDPOINTS KEY SECONDARY Overall survival SECONDARY Efficacy : ORR Safety : TESAEs, AEs of special interest Quality of life : EORTC QLQ - C30 and EQ - 5D - 5L STEP 2 Final OS analysis BLA Submission in 2027 additional patients STEP 1 Final PFS analysis Topline data disclosure based on final analysis 1 for PFS in 1H 2027 Patient enrollment
Cell Therapy Manufacturing Facility To Support Planned Anzu - cel BLA and Commercialization 21 Anzutresgene autoleucel ( anzu - cel, formerly IMA203); BLA: Biologics License Application PRAME Wave 1: anzu - cel • ~100,000 sq ft s tate - of - the - art research & GMP manufacturing facility • Modular design for efficient and cost - effective scalability - total of 8 manufacturing suites, plus further expansion space • Capacity sufficient to serve early - stage and registration - directed clinical trial as well as planned initial commercial supply • In - house manufacturing and QC allows full control of process, product and costs • Located in the Houston, Texas, Metropolitan Area offering economic labor and operating costs and talent pool highly qualified in cell therapy manufacturing & QC
PRAME WAVE 2 IMA203CD8 PRAME Cell Therapy Expansion to all Advanced PRAME Cancers
IMA203CD8 PRAME Cell Therapy: Expansion of Commercial Opportunity to all Advanced PRAME+ Solid Tumors 23 All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025; Source: Internal Forecast 2026; EU5: France, Germany, Italy, Spain, United Kingdom 1 Bajwa et al. 2021 Journal for Immunotherapy of Cancer; 2 Melenhorst et al. 2022 Nature, Bai et al. 2022 Science Advances; 2L: patients with unresectable or metastatic solid tumors who have received at least 1 prior therapy; sqNSCLC : squamous cell non - small - cell lung cancer, HNSCC: head and neck squamous cell carcinoma The PRAME + /HLA - A*02:01 + addressable patient opportunity across a broad range of PRAME expression is > 75K per year • Co - transduction of CD8αβ alongside PRAME TCR adds functional CD4 + T cells designed to boost cytotoxicity • Proof of concept from preclinical experiments 1 and CD19 CAR T cell studies in leukemia 2 • Based on its enhanced pharmacology, IMA203CD8 provides the potential to expand to tumor - agnostic label in 2L PRAME cancers across broad spectrum of PRAME expression level (see appendix for PRAME expression levels) • Ovarian carcinoma chosen as initial proof - of - concept PRAME Wave 2: IMA203CD8 IMA203CD8 Opportunity 2L Solid Tumors EU5 US 2K 2K Ovarian 4K 4K Uterine 10K 7K sqNSCLC 2K 2K HNSCC 8K 5K Breast 18K 16K Others TUMOR CELL DEATH CD8 - engineered CD4 T CELL Cytotoxic Activity CD8 T CELL T cell Help Cytotoxic Activity CD8 PRAME TCR
Towards Proof - of - concept for Tumor - agnostic Targeting of PRAME Cancers with IMA203CD8 24 a Being conducted at Hopp Children's Cancer Center Heidelberg ( KiTZ ), Germany; cPR , confirmed partial response; IIT, investigator - initiated trial; TEAE, treatment - emergent adverse events Summary: IMA203CD8 Cell Therapy in PRAME+ Solid Tumors Data cutoff August 7, 2026 PRAME Wave 2: IMA203CD8 • Completion of Phase 1b uterine cancer cohort expected in 1H 2027 • Planned start of pediatric Phase 1/2 IIT a in PRAME - positive solid tumors in 1H 2027 Clinical activity across tumor types with distinct biology and differing levels of PRAME expression supports the broad applicability of IMA203CD8 across PRAME - positive cancers and its tumor - agnostic development Development Opportunity • One - time infusion of IMA203CD8 showed clinical anti - tumor activity across multiple tumor types with distinct biology and differing levels of PRAME expression • 51% ORR, 41% cORR , including multiple complete responses, and tumor reduction in 83% of patients across all dose levels and indications • Gynecologic cancers (platinum - pretreated ovarian cancer and uterine cancer) at clinically relevant doses (≥DL4c): 60% ORR, 55% cORR , incl. complete responses; mDOR 8.4 months, mPFS 5.8 months, and mOS not reached ( mFU : 7.8 months) • Synovial sarcoma at low doses: 67% ORR and 67% cORR , including one complete response, and ongoing responses up to ~3 years across all doses at low median dose Activity Across PRAME+ Tumors • Most frequent TEAEs were expected • Transient cytopenias associated with lymphodepletion • Mostly low - grade CRS • Infrequent ICANS • Potential for outpatient administration Manageable Tolerability
Phase 1 Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors 25 PRAME Testing Biopsy or archived tissue No longer required for indications with high PRAME prevalence, including ovarian and uterine cancer, melanoma, and synovial sarcoma IMA203CD8 Manufacturing (~2 weeks) Lymphodepletion Fludarabine 30 mg/m 2 Cyclophosphamide 500 mg/m 2 days - 6 to - 3 ц Low Dose IL - 2 a 1M IU SUBQ QD, days 3 - 5, then 1M IU SUBQ BID, days 6 - 10 Leukapheresis HLA - A*02:01 Testing (blood) Patient Journey SCREENING/MANUFACTURING TREATMENT/OBSERVATION FOLLOW UP IMA203CD8 one - time infusion Key Objectives Primary: • Tolerability • Determination of RP2D Secondary: • Efficacy • Pharmacokinetics Key Eligibility Criteria • Advanced or metastatic solid tumors • Age ≥18 years • ECOG PS 0 - 1 • HLA - A*02:01 positive • PRAME positive • No available SOC treatment options • Measurable disease (RECIST 1.1) • Adequate organ function Dose escalation completed Enrichment at relevant DLs (≥DL4c): ~1.2 – 12.5 billion total TCR T cells DL3 (n=7) 0.44 - 1.00 × 10 9 total TCR T cells DL4a (n=38) 0.93 - 1.86 × 10 9 total TCR T cells DL4b (n=4) 1.49 - 2.05 п 10 9 total TCR T cells DL5 (n=7) 1.95 - 4.30 п 10 9 total TCR T cells DL6 (n=15) 3.55 - 8.22 п 10 9 total TCR T cells DL7 (n=17) 4.26 - 12.50 × 10 9 total TCR T cells Dose Escalation Scheme ц Low Dose IL - 2 a DL4c (n=9) 1.15 - 3.06 п 10 9 total TCR T cells a Dose level ≥DL4c is evaluated “ IL - 2, starting without IL - 2. If tolerable, add IL - 2 at the same dose or escalate to next dose without IL - 2; outpatient IL - 2 admi nistration at investigator’s discretion. Anzu - cel, anzutresgene autoleucel; bid, twice daily; BSA, body surface area; DL, dose level; ECOG, Eastern Cooperative Oncology Group; HLA, human le uk ocyte antigen; IL, interleukin; IU, international unit; PRAME, preferentially expressed antigen in melanoma; PS, performance status; qd , once daily; RP2D, recommended phase 2 dose; SOC, standard of care; SUBQ, subcutaneous; TCR, T - cell receptor. Data cutoff August 7, 2026 Busse et al., ESMO 2026 PRAME Wave 2: IMA203CD8 IMA203 - 101: NCT03686124; Based on initial safety data observed with anzu - cel (IMA203), IMA203CD8 dose escalation was initiated at DL3. Total TCR T cells calculated from defined number of TCR T cells/m 2 BSA per dose level î 1.8 m 2 BSA.
IMA203CD8 PRAME Cell Therapy: Patient Disposition 26 Safety Population a N=98 Efficacy - evaluable Population b n=90 Gynecologic Indications n=27 Melanoma n=44 Synovial Sarcoma n=12 Other n=7 n=7 n=20 n=28 n=16 n=11 n=1 n=2 n=5 <DL4c ≥DL4c Gynecologic indications include ovarian cancer and uterine cancer ; melanoma includes cutaneous , uveal , mucosal , acral melanoma , and melanoma of unknown primary ; other indications include breast and non - small cell lung cancer . a All patients who started lymphodepletion . b All patients who received IMA203CD8 infusion and had ≥1 postbaseline scan, progressive disease or death. DL, dose level; EOT, end of treatment. Data cutoff August 7, 2026 Busse et al., ESMO 2026 PRAME Wave 2: IMA203CD8 n=1 lymphodepleted, but not infused n =4 pending first postbaseline scan n =1 consent withdrawn before assessment n =1 EOT before first scan n =1 no measurable disease at baseline
IMA203CD8: Baseline Characteristics 27 Efficacy - evaluable Population b Safety Population a Other n=7 Synovial Sarcoma n=12 Melanoma n=44 Gynecologic Indications n=27 All N=98 56 (38 - 71) 46 (20 - 66) 62 (23 - 85) 58 (35 - 75) 58 (20 - 85) Median age (range), years 4 (57) 4 (33) 22 (50) 27 (100) 63 (64) Female, n (%) 4 (57) 2 (17) 21 (48) 10 (37) 40 (41) ECOG PS 1, n (%) 5 (71) 4 (33) 21 (48) 11 (41) 43 (44) LDH ≥1 × ULN, n (%) 6.4 (3.9 - 14.7) 8.1 (1.2 - 41.1) 7.9 (1.3 - 43.4) 6.2 (1.1 - 21.6) 6.8 (1.1 - 43.4) Median target lesion SLD (range), cm c 6 (5 - 25) 8 (1 - 16) 4 (1 - 25) 5 (1 - 25) 5 (1 - 25) Median number of tumor lesions (range) c 3 (43) 1 (8) 25 (57) 14 (52) 45 (46) Liver metastasis, n (%) 1 (14) 0 (0) 7 (16) 0 (0) 9 (9) Brain metastasis, n (%) 4 (57) 2 (17) 7 (16) 3 (11) 16 (16) Bone metastasis, n (%) 2 (29) 1 (8) 9 (20) 17 (63) 32 (33) Peritoneal disease, n (%) a All patients who started lymphodepletion. b All patients who received IMA203CD8 infusion and had ≥1 postbaseline scan, progressive disease or death. Gynecologic indications include ovarian cancer and uterine cancer ; melanoma includes cutaneous , uveal , mucosal , acral melanoma , and melanoma of unknown primary ; other indications include breast cancer and non - small cell lung cancer . c Two patients were excluded from the target lesion analysis due to unavailable target lesion measurements at the time of data cut off. ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PS, performance status; SLD, sum of longest diameter; U LN, upper limit of normal. Data cutoff August 7, 2026 Busse et al., ESMO 2026 PRAME Wave 2: IMA203CD8
IMA203CD8: Treatment Experience 28 Efficacy - evaluable Population b Safety Population a On Study Other n=7 Synovial Sarcoma n=12 Melanoma n=44 Gynecologic Indications n=27 All N=98 1.95 (1.47 - 10.00) 1.59 (0.89 - 10.00) 1.67 (0.44 - 11.80) 3.55 (0.47 - 12.50) 1.81 (0.44 - 12.50) Total infused dose TCR T cells [ × 10 9 ], median (range) Efficacy - evaluable Population b Safety Population a Prior Therapy Other n=7 Synovial Sarcoma n=12 Melanoma n=44 Gynecologic Indications n=27 All N=98 6 (86) 7 (100) 9 (75) 12 (100) 31 (70) 43 (98) 5 (19) 27 (100) 53 (54) 97 (99) Treatment, n (%) Radiation Systemic treatment 4 (2 - 7) 6 (86) 2 (1 - 5) 5 (42) 3 (0 - 9) 37 (84) 4 (1 - 7) 22 (81) 3 (0 - 9) 77 (79) Lines of systemic treatment, median (range) ≥3, n (%) 6 (86) 7 (100) - - - 5 (71) 0 0 12 (100) - - - 5 (42) 1 (8) 39 (89) 14 (32) - - - 15 (34) 15 (34) 5 (19) 27 (100) 24 (100) 19 (79) 1 (0 - 4) 23 (85) 0 55 (56) 68 (69) - - - 54 (55) 18 (18) Immune checkpoint inhibitors, n (%) Chemotherapy, n (%) Ovarian cancer only (n=24): Lines of prior platinum - based therapy, n (%) Platinum - resistant, n (%) Lines post - platinum resistance, median (range) Targeted therapies (ie, ADCs, TKIs), n (%) TCR - based therapies, n (%) a All patients who started lymphodepletion. b All patients who received IMA203CD8 infusion and had ≥1 postbaseline scan, progressive disease or death. Gynecologic indications include ovarian cancer and uterine cancer ; melanoma includes cutaneous , uveal , mucosal , acral melanoma , and melanoma of unknown primary ; other indications include breast cancer and non - small cell lung cancer . ADC, antibody drug conjugate; TKI, tyrosine kinase inhibitor; TCR, T - cell receptor. Data cutoff August 7, 2026 Busse et al., ESMO 2026 PRAME Wave 2: IMA203CD8
Tolerability of IMA203CD8 in Advanced Solid Tumors 29 • Most frequent TEAEs were cytopenias associated with lymphodepletion • CRS was mostly grade 1 - 2 • DLTs in 4 of 98 patients: 1. DL4b: grade 4 neurotoxicity/CRS with grade 3 HLH 2. DL4b: grade 3 CRS 3. DL5: grade 3 ICANS b 4. DL7: grade 4 skin infection b • Late grade 3 - 4 N - ICAHT in 5 patients was manageable with supportive treatment ; all improved to grade ≤2 at a median of 69 days postinfusion (range, 42 – 121) • No IMA203CD8 - related grade 5 event c • MTD not reached with doses up to 12.5 billion IMA203CD8 cells TEAEs in ≥20% of Patients ( N=98 a ) Grade ≥3 Any grade Preferred term, n (%) 97 (99) 98 (100) Patients with any adverse event 87 (89) 88 (90) Neutropenia 54 (55) 78 (80) Anemia 36 (37) 71 (72) Thrombocytopenia 2 (2) 64 (65) Nausea 45 (46) 45 (46) Lymphopenia 5 (5) 39 (40) Rash 6 (6) 37 (38) Fatigue 12 (12) 37 (38) Transaminase elevation 2 (2) 34 (35) Hypokalemia 0 33 (34) Constipation 0 28 (29) Vomiting 3 (3) 26 (27) Abdominal pain 23 (23) 25 (26) Leukopenia 2 (2) 23 (23) Hyponatremia 0 23 (23) Pyrexia 3 (3) 21 (21) Hypophosphatemia 3 (3) 20 (20) Diarrhea 1 (1) 20 (20) Headache Adverse Events of Special Interest ( N=98 a ) 94 (96) CRS, any grade, n (%) 38 (39) Grade 1 47 (48) Grade 2 8 (8) Grade 3 1 (1) Grade 4 7 (7) HLH, any grade, n (%) 0 Grade 1 4 (4) Grade 2 2 (2) Grade 3 1 (1) Grade 4 8 (8) ICANS, any grade, n (%) 5 (5) Grade 1 1 (1) Grade 2 2 (2) Grade 3 Late N - ICAHT Beyond Day 28 ( N=87) 20 (23) ICAHT, any grade, n (%) 15 (17) Grade 1 - 2 5 (6) Grade 3 - 4 All TEAEs occurring in at least 20 patients ( ≥20%) are presented. Grades were determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Grades for CRS and ICANS were determined according to CARTOX criteria ( Neelapu et al, 2018 before protocol v11.0; Neelapu et al, from protocol v11.0 onward ) Late neutropenia - based Immune Effector Cell – Associated Hematotoxicity (N - ICAHT) grade was based on the second - lowest absolute neutrophil count between days 28 - 100 postinfusion and required ≥2 neutropenic measurements during this period , including ≥1 between days 35 - 60. Measurements before the day 28 visit were not used for late ICAHT grading but were considered when determining neutropenia onset and duration . Day 28 visits could have occurred ± 3 days before or after day 28. Assessments were available for n=87 patients . a All patients who started lymphodepletion, including 1 patient who did not receive IMA203CD8 cells. b 2 events met DLT criteria but did not limit dose escalation: 1 in an enrichment cohort at DL5 and 1 at highest dose, DL7 (1/6 p atients), both within protocol - defined dose - finding rules. c Possibly related grade 5 event as previously reported was determined by the PI to be unlikely related to IMA203CD8 after comp le te assessment. Patient died from sepsis that was aggravated by immunosuppression from fludarabine/cyclophosphamide (possibly related), a grade 4 HLH event, the toxicity management, and rap idl y progressing disease. CARTOX, CAR T - cell therapy – associated toxicity; CRS, cytokine release syndrome; DL, dose level; DLT, dose - limiting toxicity; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell – associated neuroto xicity syndrome; PI, principal investigator; MTD, maximum tolerated dose; TEAE, treatment - emergent adverse event. Data cutoff August 7, 2026 Busse et al., ESMO 2026 PRAME Wave 2: IMA203CD8
'DWDFXW  RII
      3DWLHQWVDUHRUGHUHGE\EHVWSHUFHQWDJHFKDQJHZLWKLQHDFKVXEJURXS  6XEJURXSRUGHU
  6HOHFWHGVXEJURXSEORFNV :DWHUIDOO3ORW 2QJRLQJ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH
5(&,67   
                                                                                              
         
        
                                    
      *\Q2QF 0HODQRPD 6\QRYLDO6DUFRPD 2WKHU 'RVH/HYHO           7DUJHW/HVLRQVIURP%DVHOLQH
5(&,67   
%HVW  &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI %DVHOLQH * * * Tumor Reduction Achieved by IMA203CD8 Across Dose Levels During Dose Escalation by Indication 30 BOR (RECIST 1.1) PD Ongoing response/disease control SD PR cPR CR cCR * Confirmed response based on prior PR that deepened to CR n=2 patients with ovarian cancer and n=1 patient with melanoma died before first postbaseline scan and n=1 additional patient wi th melanoma had a non - evaluable target lesion; these patients are not depicted in the plot but were included in the ORR, cORR and DCR calculation. ORR: according to RECIST 1.1 at any postbaseline scan, PD or death at any prior timepoint; Confirmed ORR f or patients with ≥2 postbaseline scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfirmed PR/CR were excluded. For patients achieving a (c)CR with <100% change from baseline , t arget lesions were lymph nodes that resolved to <10 mm per RECIST 1.1. Gynecologic indications include ovarian cancer and uterine cancer; melanoma includes cutaneous, uveal, mucosal, acral melanoma, and melanoma of unknown prima ry; other indications include breast cancer and non - small cell lung cancer. BOR, best overall response; (c)CR, (confirmed) complete response; DCR, disease control rate; (c)ORR, (confirmed) objective response rate; PD, progressive di sease; (c)PR, (confirmed) partial response; SD, stable disease. Data cutoff August 7, 2026 Busse et al., ESMO 2026 PRAME Wave 2: IMA203CD8 Gynecologic Indications (n=27) Melanoma (n=44) Synovial Sarcoma (n=12) Other (n=7) ALL (n=90) 1.95 1.59 1.67 3.55 1.77 Median dose [x10 9 total TCR T cells ] 29 % (2/ 7 ) 67% (8/12) 52 % (23/44) 48 % ( 13 / 27 ) 51% (46/90) ORR 0 % ( 0 / 6 ) 67% (8/12) 41 % ( 17 / 42 ) 41 % ( 11 / 27 ) 41% (36/87) cORR 100% (7/7) 100% (12/12) 8 2 % ( 36 / 44 ) 70% (1 9 / 27 ) 82% (74/90) DCR 86% (6/7) 92% (11/12) 8 8 % ( 37 / 42 ) 68% ( 17 / 25 ) 83% (71/86) Tumor reduction
Changes in Tumor Size Over Time after Treatment with IMA203CD8 31 3' 3' %DVHOLQH %DVHOLQH 35 35   
       
  0RQWKVSRVW7FHOOLQIXVLRQ              &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW/HVLRQVIURP%DVHOLQH >@ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH
5(&,67   
2QJRLQJ 6SLGHU 3RSXODWLRQ
 (IILFDF\$QDO\VLV6HW  ,0$  &'  0DUNHUV
 'RW 'DWDFXW  RII
      BOR (RECIST 1.1) PD Ongoing response/disease control SD PR cPR CR cCR Months post T - cell infusion BOR, best overall response; (c)CR, (confirmed) complete response; mFU , median follow - up; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease Data cutoff August 7, 2026 Busse et al., ESMO 2026 PRAME Wave 2: IMA203CD8 All dose levels: Deep and durable responses observed across all indications with ongoing responses beyond 2.5 years ( mFU time of mPFS : 12.8 months )
Responses of Metastatic Lesions after Treatment with IMA203CD8 32 Melanoma Gynecologic indications Synovial sarcoma Other n=87 a              /HVLRQ %HVW  &KDQJHIURP%DVHOLQHSHU7DUJHW
Q 
$EGRPHQ  3HULWRQHXP
Q 
/LYHU
Q 
/XQJ
Q 
/\PSKQRGH
Q 
2WKHU 2WKHUV 6\QRYLDO6DUFRPD *\Q2QF 0HODQRPD ,QGLFDWLRQ %HVW  &KDQJHIURP%DVHOLQHSHU7DUJHW/HVLRQ ($6
  SDWLHQWV   WDUJHWOHVLRQV %R[SORWV\PEROV
 FRORUHGGRW  RQHWDUJHWOHVLRQ
FRORULQGLFDWHVPDLQLQGLFDWLRQJURXS
 ER[  LQWHUTXDUWLOHUDQJH
 WK   WKSHUFHQWLOH
 OLQHLQVLGHER[  PHGLDQ
 ZKLVNHUV  PRVWH[WUHPHQRQ  RXWO\LQJYDOXHV  5HIHUHQFHOLQHV
 GDVKHGJUH\    DQG   
 VROLGJUH\    9DOXHVLQSDUHQWKHVHVEHORZHDFKORFDWLRQDUHWKHQXPEHURIWDUJHWOHVLRQVFRQWULEXWLQJWRWKDWER[SORW  /RFDWLRQVJURXSHGLQWR2WKHU
 %RQH  %UHDVW  &HUYLFDO1HFN  &KHVW  &RORQ  (VRSKDJXV  *DVWULF  .LGQH\  2WKHU  3HOYLV  3OHXUDO(IIXVLRQ  6NLQ  9DJLQD %HVWFKDQJHLVWKHPLQLPXPSRVW  EDVHOLQHSHUFHQWFKDQJHIURPEDVHOLQHDPRQJ$1/  )/
<
 DVVHVVPHQWV  'DWDFXW  RII
      ($6SDWLHQWVQRWUHSUHVHQWHGLQWKLVILJXUH
1 
     
1RSRVW  EDVHOLQHWDUJHW  OHVLRQ6/'DVVHVVPHQW
     
1RSRVW  EDVHOLQHWDUJHW  OHVLRQ6/'DVVHVVPHQW
     
1RSRVW  EDVHOLQH WDUJHW  OHVLRQ6/'DVVHVVPHQW b Data cutoff August 7, 2026 Busse et al., ESMO 2026 PRAME Wave 2: IMA203CD8 Each data point represents reduction of a target lesion . Total number of target lesions evaluated : 241. a Best overall response of target lesions not available for n=3 patients . Gynecologic indications include ovarian cancer and uterine cancer ; melanoma includes cutaneous , uveal , mucosal , acral melanoma , and melanoma of unknown primary ; other indications include breast cancer and non - small cell lung cancer . b Other: bone , breast , cervical neck, chest , colon , esophagus , gastric , kidney , pelvis , pleural effusion , skin , vagina , and other investigator specified locations .
  
  0RQWKVSRVW7FHOOLQIXVLRQ              %DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW/HVLRQVIURP 3' %DVHOLQH 35 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH
5(&,67   
2QJRLQJ 6SLGHU 3RSXODWLRQ
 (IILFDF\$QDO\VLV6HW  *\Q2QF%XQGOH  ,0$  &'  LQ'/  FRUKLJKHU 0DUNHUV
 'RW 'DWDFXW  RII
      'DWDFXW  RII
      ;  D[LV
 ,QGLFDWLRQ 3RSXODWLRQ
 *\Q2QF%XQGOH  ,0$  &'  LQ'/  FRUKLJKHU :DWHUIDOO 2QJRLQJ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH
5(&,67   
                                ,QGLFDWLRQ           /HVLRQVIURP%DVHOLQH
5(&,67   
%HVW  &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW %DVHOLQH Antitumor Activity of IMA203CD8 at Higher Doses ≥DL4c in Patients with Gynecologic Indications 33 BOR (RECIST 1.1) PD Ongoing response/disease control SD PR cPR CR cCR * Confirmed response based on prior PR that deepened to CR * Ovarian cancer Uterine cancer Uterine Cancer Ovarian Cancer Gynecologic Indications N=20 2/2 56% (10/18) 60% (12/20) ORR 2/2 50% (9/18) 55% (11/20) cORR 2/2 67% (12/18) 70% (14/20) DCR (at week 6) 2/2 65% (11/17) 68% (13/19) Tumor reduction # Months post T - cell infusion 8.4 (2.1+, 12.2) 6.0 mDOR (range), months mFU # PRAME Wave 2: IMA203CD8 n= 1 patient with ovarian cancer died prior to first post baseline scan not evaluable for assessment of tumor reduction, not depicted in plot but included in ORR, cORR and DCR calculation ; ORR : according to RECIST 1 . 1 at any postbaseline scan, PD or death at any prior timepoint ; Confirmed ORR for patients with ≥ 2 postbaseline scans per RECIST 1 . 1 , PD or death at any prior timepoint, those with ongoing unconfirmed PR/CR were excluded . For those patients achieving a (c)CR with < 100 % changes from baseline, target lesions were lymph nodes that resolved to < 10 mm per RECIST 1 . 1 . # Ongoing confirmed PR (RECIST 1 . 1 ) as of last scan at month 7 . 5 , suspected clinical progression by clinical site at month 6 in discrepancy to RECIST response due to tumor marker increase ; patient off study at month 8 and receiving further anti - tumor treatment . Initially reported unconfirmed CR according to database entry by site referred to a lesion incorrectly classified as target lesion . Retrospective review determined that patient has no measurable target lesion at baseline and was therefore removed from efficacy population . BOR, best overall response; (c)CR, (confirmed) complete response; DCR, disease control rate; DL, dose level; (c)ORR, (confirm ed) objective response rate; mDOR , median duration of response; mFU , median follow - up; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease. Data cutoff August 7, 2026 Busse et al., ESMO 2026
IMA203CD8 Ongoing Trials and Development Approach 34 a Data on file. b Clinical data as part of an individual experimental treatment attempt with a TCR T - cell therapy in a pediatric patient using Imm atics PRAME - directed TCR published in Mair K, Rossi C, Westhoff JH, et al. PRAME - Specific T - Cell Therapy in Advanced Pediatric Nephroblastoma. N Engl J Med. 2026;395(7):721 - 724; c Exemplary number assuming bundle of PRAME+/HLA - A*02:01+ patients in the US: 2L uterine cancer, 2L platinum - refractory ovarian cancer, adult and pediatric met. sarcoma; Source: Internal Forecas t 2026 Clinical activity across PRAME - positive tumors, independent of tumor type, biology, and PRAME expression level, supports broader development with the goal of expanding into all advanced PRAME - positive cancers TUMOR - AGNOSTIC DEVELOPMENT 3 Advance selected tumor types with high PRAME expression in targeted cohorts to build the clinical evidence base for broader development Potential addressable population for this bundle is >10,000 patients in US alone c Uterine Cancer Ovarian Cancer Rare Cancers Pediatric Cancers b BUNDLE DEVELOPMENT 2 Pediatric voucher opportunity : Potential eligibility for a Priority Review Voucher through development of a qualifying pediatric indication Anti - tumor activity observed across multiple PRAME - positive tumor types with diverse biology and PRAME expression level CLINICAL PROOF - OF - CONCEPT 1 Ovarian Cancer Uterine Cancer Melanoma Synovial Sarcoma Brain metastases a PRAME Wave 2: IMA203CD8
PRAME WAVE 3 IMA402 PRAME Bispecific Expansion to Earlier - Line PRAME Cancers
IMA402 Opportunity 36 a Half - life calculated by non compartmental analysis (NCA); All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025 based on initial threshold for all indications except for sqNSCLC (optimized threshold considered for further development due to IMA401 combination potential); Source: Internal Forecast 2026; E U5: France, Germany, Italy, Spain, United Kingdom; q2w: once every two weeks; sqNSCLC : squamous cell non - small - cell lung cancer 1L Solid Tumors >145K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 TCR Bispecifics (TCER®) PRAME Wave 3: IMA402 EU5 US 6K 6K Cut. Melanoma 9K 7K Ovarian 6K 6K Uterine 23K 16K sqNSCLC 10K 7K Breast 32K 25K Others CD3/TCR Activated T cell Tumor Cell PRAME IMA402 x Antitumor Activity High - affinity and specificity TCR domain targeting PRAME pHLA molecules x Antibody - like format with half - life extension Long half - life of >1 week a allows for q2w or longer dosing intervals x Optimized tolerability Low - affinity T - cell recruiter against CD3/TCR allows higher dosing IMA402 PRAME Bispecific: Expansion of the Commercial Opportunity to Earlier - Line PRAME+ Cancers
Cancer Cell IMA402 PRAME Bispecific Summary: Phase 1 Dose Escalation Study 37 Tolerability Activity & Duration of Response Pharmacokinetics Development Potential Favorable tolerability profile Most frequent treatment - related AEs are low - grade CRS and expected & transient lymphopenia • Promising anti - tumor activity with deep and durable responses • 25% cORR at RP2D range across all indications • 32% cORR across all PRAME high indications • 32% cORR , 12.5 months mDOR and 91% 1 - year OS rate in PRAME high melanoma Median half - life of >1 week Bi - weekly dosing introduced and potential for longer dosing intervals, offering a convenient dosing schedule , including for combination treatment approaches Clinical profile of IMA402 reinforces development path across multiple solid tumor indications, including melanoma, gynecologic cancers and lung cancer, in earlier and later treatment lines, supported by Immatics’ innovative, rapid liquid biopsy - based PRAME testing AE: adverse event; CRS: Cytokine release syndrome; ICI: immune checkpoint inhibitor; RP2D: recommended phase 2 dose; SOC: standard of care Data cutoff Jun 1, 2026 PRAME TCER® IMA402 PRAME Wave 3: IMA402 • First data on IMA402 combination cohorts incl. IMA402/IMA401 in sqNSCLC : 2027
Phase 1 Phase 1/2 Trial Design to Evaluate IMA402 PRAME Bispecific 38 • MABEL - based starting dose • Dose escalation based on cohorts of 1 - 6 patients using adaptive design (BLRM model) • MTD not reached per adaptive BLRM model • q1w step dosing (3 doses) up to target dose b • q2w dosing from week 7 introduced post data cutoff based on favorable pharmakokinetics • IMA402 RP2D range: 10 - 45 mg Key Eligibility Criteria Key Objectives Primary: • Determine MTD and/or RP2D • Assess safety and tolerability Secondary: • Evaluate initial antitumor activity (RECIST 1.1 and iRECIST ) • Assess pharmacokinetics • Recurrent and/​or refractory solid tumors expressing PRAME a • No prospective PRAME testing required • HLA - A*02:01 positive • ECOG performance status 0 - 1 • Received or not eligible for all available indicated standard of care treatments EudraCT No. 2022 - 503133 - 54 - 00; NCT05958121. a Cutaneous melanoma, melanoma of unknown primary, uveal melanoma, synovial sarcoma, endometrial carcinoma, ovarian carcinoma, sq uamous non - small cell lung cancer. b Step dosing introduced at 0.36 mg, optimized step dosing: 0.03 mg/0.3 mg/10 mg/target dose, low - dose dexamethasone used as preventive measure for initi al doses as applied for other bispecific T - cell engagers; ability to increase dose to previously cleared dose levels. c Exploratory high dose in n=5. d Efficacy population: All patients treated within the RP2D range as of Mar 1, 2026 (who had the opportunity for at least 3 mon th s follow - up or who discontinued early due to disease progression or death), tested positive for PRAME, received ≥4 infusions as defined per protocol (thereof 3 step doses, currently at 0.03 mg/0.3 mg/10 mg, and 1 target dose), and had LDH ≤1.5xULN . BLRM, Bayesian logistic regression model; ECOG, Eastern Cooperative Oncology Group; MABEL, minimum anticipated biological effect level; MTD, maximum tolerated dose; q1w, every week; q2w, every 2 weeks; RP2D, r eco mmended phase 2 dose. PRAME Wave 3: IMA402 Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 0.36 mg 0.8 mg 3 mg 5 mg 0.12 mg 1.6 mg 0.06 mg 0.02 mg 8 mg 4 mg 12 mg 20 mg 30 mg 10 mg 45 m g c Efficacy Population d (n=40) Safety Population (N=126) IMA402 Monotherapy IMA402 + Pembrolizumab 10 mg + pembrolizumab 5 mg + pembrolizumab 20 mg + pembrolizumab 30 mg + pembrolizumab
Demographics: Heavily Pretreated Patient Population Enrolled in IMA402 Trial 39 Efficacy Population Safety Population n=40 N=126 Baseline Characteristics 27 - 26, 1, 0 8 5 - 2, 2, 1 78 - 62, 13, 3 31 17 - 7, 6, 4 Indication, n Melanoma - cutaneous, uveal, unknown primary Ovarian cancer Other - endometrial cancer, sqNSCLC, synovial sarcoma 59 (29 - 77) 60 (21 - 82) Age Median (range) 25 (63) 15 (38) 78 (62) 48 (38) ECOG performance status 0, n (%) 1, n (%) 10 (25) 57 (45) LDH at baseline >1xULN, n ( %) 7.9 (1.5 - 19.4) 7.4 (1.2 - 39.8) Baseline tumor burden Median target lesion sum of diameter (cm) (range) 4 (2 - 10) 11 (28) 3 (8) 4 (1 - 15) 44 (35) 7 (6) Tumor lesions Number of lesions, median (range) Liver metastases, n (%) Brain metastases, n (%) Treatment Experience 3 (0 - 6) 3 (0 - 7) No. of prior lines of systemic treatment Median (range) 19 (48) 31 (78) 18 (45) 60 (48) 89 (71) 60 (48) Prior systemic treatments, n (%) Chemotherapy ICI Targeted therapy ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; sqNSCLC , squamous non - small cell lung cancer; ULN, upper limit of normal. PRAME Wave 3: IMA402 Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026
Safety Profile of IMA402 Across All Indications and Dose Levels (N=126) 40 AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRS, cytokine release syndrome; ICANS, imm une effector - cell associated neurotoxicity syndrome; TEAE, treatment - emergent AE; TRAE, treatment - related AE. PRAME Wave 3: IMA402 Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 • Most frequent related AEs were: • Transient lymphopenia (resolved within a median of 5d) • Low - grade CRS • One CRS G4 event at 0.08 mg starting dose only; no further CRS G4 events after step dose optimization • One CRS G3 event at 0.03 mg starting dose only, completely resolved within 7d • No ICANS observed • No IMA402 - related G5 events No additive toxicity was observed in patients treated with IMA402 + pembrolizumab a TRAEs : All treatment - emergent adverse events at least possibly related to IMA 402 with grade 1 - 2 occurring in at least 9 patients (incidence ≥ 7 . 1 % ) , and all events with grade ≥ 3 . One uncoded grade 1 AE (“ spotting ”) is not included . Abdominal pain includes “Abdominal Pain” and "Abdominal Pain Upper ” ; Adverse events are coded using the MedDRA Version 26 . 0 . Grades are determined according to National Cancer Institute CTCAE, version 5 . 0 , except grades for CRS and ICANS which are determined according to Lee et al . , 2019 ; Neelapu et al . , 201 9 and tumor lysis syndrome which is determined according to Cairo and Bishop, 2004 . Patients are counted only once per adverse event . ≥ Grade 3 All Grades Treatment - related AEs, n (%) a 44 (35) 56 (44) Lymphopenia 2 (2) 46 (37) Cytokine release syndrome 2 (2) 42 (33) Arthralgia 1 (1) 32 (25) Fatigue 10 (8) 23 (18) ALT/AST increased 0 18 (14) Pruritus 0 18 (14) Pyrexia 4 (3) 17 (13) Anaemia 1 (1) 17 (13) Myalgia 0 16 (13) Rash 4 (3) 12 (10) Gamma - glutamyltransferase increased 1 (1) 10 (8) Nausea 0 10 (8) Erythema 4 (3) 9 (7) Lipase increased 0 9 (7) Diarrhoea 1 (1) 9 (7) Abdominal pain 3 (2) 4 (3) Hypertension 1 (1) 4 (3) Leukopenia 1 (1) 4 (3) Vomiting 1 (1) 3 (2) Blood creatinine increased 1 (1) 3 (2) Tumour pain 2 (2) 2 (2) Neutropenia 1 (1) 2 (2) Back pain 1 (1) 2 (2) Pancreatitis 1 (1) 2 (2) Stomatitis 1 (1) 2 (2) Urinary tract disorder 1 (1) 1 (1) Acute kidney injury 1 (1) 1 (1) Electrocardiogram abnormal 1 (1) 1 (1) Herpes zoster 1 (1) 1 (1) Immune - mediated arthritis 1 (1) 1 (1) Liver function test increased 1 (1) 1 (1) Tumour lysis syndrome ≥ Grade 3 All Grades Treatment - emergent AEs, n (%) 81 (64) 125 (99) Any 65 (52) 120 (95) Treatment - related
Efficacy of IMA402 ± Pembrolizumab Across All Indications in the Efficacy Population 41 IMA402 monotherapy IMA402 + pembrolizumab Melanoma a Ovarian cancer Other indications b BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing response/ disease control Ongoing treatment Confirmed responses in ICI - pretreated melanoma and platinum - pretreated ovarian cancer All Indications (n=40) 25% (10/40) cORR 63% (25/40) DCR (week 6) a Includes cutaneous melanoma and 1 patient with uveal melanoma. b Includes endometrial cancer (n=2), sqNSCLC (n=2), and synovial sarcoma (n=1). BOR, best overall response; BL, baseline; cCR , confirmed complete response; cORR , confirmed objective response rate; DCR, disease control rate; ICI, immune checkpoint inhibitor; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease. Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 PRAME Wave 3: IMA402
IMA402 PRAME Bispecific: Exploratory Analysis of PRAME Levels and Disease Outcome in Efficacy Population 42 PRAME mRNA expression relative to threshold PRAME low : 1 - 3x expression level PRAME high : >3x expression level PRAME negative: below threshold n=40 Tumor Reduction Efficacy Population All Indications # • IMA402 shows association of higher PRAME levels with improved disease outcomes and tumor reduction • All responders a with melanoma are PRAME high • >80% b of patients with melanoma are PRAME high BOR (RECIST 1.1) PD SD PR cPR cCR a PRAME low does not preclude response to IMA402, 1 cPR observed in a patient with PRAME low endometrial cancer below RP2D range; b Data on file: PRAME target prevalence is based on in - house (n=136) and TCGA RNAseq (n=473) analysis using proprietary mass spec - guided initial expression threshold. # Mann - Whitney U test . BOR, best overall response; cCR , confirmed complete response; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease; TCGA, The Canc er Genome Atlas. Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 PRAME Wave 3: IMA402
IMA402 PRAME Bispecific: Patient Disposition 43 Efficacy Population n=40 PRAME low n=9 a PRAME high n=31 Melanoma n=22 IMA402 Monotherapy n=20 IMA402 + Pembrolizumab n=2 Ovarian Cancer n=6 Other b n=3 • Exploratory analysis in efficacy population based on qPCR expression levels • All responders c with melanoma are PRAME high • >80% d of patients with melanoma are PRAME high a Includes 2 patients treated with IMA402 + pembrolizumab. b Other includes endometrial cancer (n=2) and synovial sarcoma (n=1). c PRAME low does not preclude response to IMA402, 1 cPR observed in a patient with PRAME low endometrial cancer below RP2D range. d Data on file: PRAME target prevalence is based on in - house (n=136) and TCGA RNAseq (n=473) analysis using proprietary mass spec - guided initial expression threshold. qPCR, quantitative polymerase chain reaction. Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 PRAME Wave 3: IMA402
Efficacy of IMA402 ± Pembrolizumab by PRAME Expression 44 BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing response/ disease control Ongoing treatment IMA402 monotherapy IMA402 + pembrolizumab Melanoma a Ovarian cancer Other indications b Ovarian Cancer Melanoma All Indications 3/6 32% (7/22) 32% (10/31) cORR 3/6 73% (16/22) 65% (20/31) DCR (week 6) PRAME high a Includes cutaneous melanoma and one patient with uveal melanoma. b Includes endometrial cancer (n=2), sqNSCLC (n=2), and synovial sarcoma (n=1). BOR, best overall response; BL, baseline; cCR , confirmed complete response; cORR , confirmed objective response rate; DCR, disease control rate; PD, progressive disease; (c)PR, (confirmed) partial response; RP2D, recommended phase 2 dose; SD, stable disease. Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 PRAME Wave 3: IMA402 PRAME low (n=9) PRAME high (n=31)
Durability of Responses with IMA402 ± Pembrolizumab in PRAME high Melanoma All Patients with Melanoma in the Efficacy Population Received prior ICI 45 32% (7/22) cORR 12.5 mo 16.8 mo mDOR mFU n=22 Not reached 8.8 mo mOS mFU 91% 1 - year OS rate Ongoing patients were censored at the data cutoff for OS; OS rates were calculated using the Kaplan – Meier method. BOR, best over all response; BL, baseline; cCR , confirmed complete response; cORR , confirmed objective response rate; ICI, immune checkpoint inhibitor; mDOR , median duration of response; mFU , median follow up; mOS , median overall survival; PD, progressive disease; (c)PR, (confirmed) partial response; RP2D, recommended phase 2 dose; SD, stable disease. Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 PRAME Wave 3: IMA402 IMA402 + Pembrolizumab BOR (RECIST 1.1) PD Ongoing response/ disease control Ongoing treatment SD PR cPR cCR Within RP2D range ( ≥ 10 mg), n=22 Below RP2D range (<10 mg), n=15
PRAME Prevalences for IMA402 Development in Selected Indications 46 Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 PRAME Wave 3: IMA402 PRAME high based on actual in - house data PRAME high TCGA PRAME low+high TCGA a Indication >80% (n=136) 92% 95% Cutaneous melanoma 60% - 95% (n=15) 95% 97% Uterine carcinoma ~60% (n=50) 64% 84% Ovarian carcinoma a PRAME target prevalence is based on TCGA RNAseq analysis using proprietary mass spec - guided initial expression threshold. Values not rounded. No screening and threshold requirement for anzu - cel and IMA203CD8. TCGA, The Cancer Genome Atlas IMA402 PRAME low threshold IMA402 PRAME high threshold PRAME low threshold : i nitial threshold in IMA402 trial PRAME high threshold : presumed threshold for IMA402 fast - track development IMA402 patient coverage based on applied thresholds:
Outlook: Liquid Biopsy for Patient Selection 47 • Proprietary liquid biopsy assay for patient selection • Few millilitres of blood sufficient • Fast, sensitive and reliable detection of PRAME in blood • Representative PRAME levels across all tumor lesions prior to treatment start Best Overall Response Efficacy Population IMA402 Monotherapy Only a Non - responder: PD, SD. Responder: PR, cPR , cCR . # Mann - Whitney U test cCR , confirmed complete response; (c)PR, (confirmed) partial response; PD, progressive disease; SD, stable disease. Data cutoff Jun 1, 2026 Schadendorf et al., ESMO 2026 PRAME Wave 3: IMA402 n=36 Liquid biopsy assay score a a # BOR (RECIST 1.1) PD SD PR cPR cCR n=36 Liquid biopsy assay score a a
Potential to Unlock >90% of sqNSCLC Patients with IMA401 + IMA402 Dual Targeting 48 Data on file - dot plot: PRAME and MAGEA4/8 mRNA expression in stage III/IV sqNSCLC TCGA samples (TPM, log - scale), PRAME and MAGEA4/8 target prevalences are based on an optimized proprietary target expression th reshold applied to TCGA data; Bar graph: In vitro LDH - killing assay, A375 tumor cell line with low target density of PRAME (~50 copies per cell) and medium target density of MAGE A4/8 (~250 copies per cell), TCER® concentration: 1nM IMA401 and 10 nM IMA402; a Refers to addressable 1L advanced HLA - A*02:01/target+ patients in the US & EU5 in 2025, Source: Internal Forecast 2026; HNSCC: head and neck squamous cel l carcinoma; sqNSCLC : squamous non - small cell lung cancer. IMA402 + IMA401 Combo PRAME+ or MAGEA4/8+ including 60% double positive > 90% PRAME MAGEA4/8 1 TARGET COVERAGE >90% of patients with sqNSCLC are targetable, potentially unlocking broad treatment coverage for ~40K patients with sqNSCLC in the US and EU per year a Expanded Patient Reach Dual targeting has the potential to improve depth and durability of tumor response by counteracting tumor heterogeneity and escape ~ 6 0% of patients with sqNSCLC express both targets Synergistic Anti - Tumor Activity In vitro model of PRAME and MAGEA4/8 double positive tumor w / o T C E R I M A 4 0 2 I M A 4 0 1 I M A 4 0 1 + I M A 4 0 2 0.0 0.2 0.4 0.6 0.8 Tumor cell killing [OD 490 nm - 650 nm ] 2 IN - VITRO TUMOR CELL KILLING IMA401 data across cancer types incl. lung: Wermke, et al. ASCO 2026. Wermke, et al. Nat Med. 2026. Bispecifics Combination with Increased Commercial Potential Expands addressable market as first step in sqNSCLC , potential for many other indications like HNSCC, esophageal squamous carcinoma, TNBC, endometrial carcinoma, ovarian carcinoma, melanoma, sarcoma and other s as next steps
IMA402 Development Path to Deliver an Off - the - Shelf PRAME Therapy 49 IMA402 Cohorts in Phase 1b Clinical Evaluation IMA402 + ICI a 2L melanoma IMA402 monotherapy 2L melanoma IMA402 + pembrolizumab Gynecologic cancers IMA402 + IMA401 sqNSCLC IMA402 + decitabine Ovarian cancer, melanoma Monotherapy in 2L PRAME - high melanoma ICI combination in earlier - line melanoma (post - adjuvant & ICI - naïve 1L melanoma) Expansion to additional cancer types Lung cancer (in combination with IMA401) Gynecologic cancers (in combination with SOC) Development Path Proprietary liquid biopsy assay for rapid PRAME testing to support efficient patient selection & accelerated development across indications IMA402 + ICI a 1L melanoma PRAME Wave 3: IMA402 a pembrolizumab or nivolumab/ relatlimab ; ICI, immune checkpoint inhibitor; ONGOING COMPLETED ONGOING ONGOING ONGOING ONGOING
Entering the PRAME Franchise IMA401 MAGEA4/8 Bispecific Maximizing the Potential of Bispecifics Combination ​
Cancer Cell MAGEA4/8 IMA401 MAGEA4/8 Bispecific Summary: Phase 1 Dose Escalation Study 51 1 at RP2D of 1 - 2 mg; AE: Adverse Event; CRS: Cytokine Release Syndrome; (c)ORR: (confirmed) objective response rate; DCR: disease control rate; ICI : immune checkpoint inhibitor; HNSCC: Head and neck squamous cell carcinoma; sqNSCLC : squamous cell non - small - cell lung cancer • 29% cORR (4/14) in head and neck cancer • 33% cORR (2/6) in melanoma • Promising early clinical activity in sqNSCLC Opportunity to develop IMA401 in combination with IMA402 in sqNSCLC and other indications Combined target prevalence supports broad patient coverage and potential synergistic activity >90% of patients with sqNSCLC are targetable Favorable tolerability at RP2D ± pembrolizumab, suggesting the potential of IMA401 for broad combinability Most frequent clinically relevant TRAE were low - grade cytokine release syndrome (CRS), expected and transient lymphopenia, consistent with the mechanism of action, and manageable neutropenia. Median terminal half - life of >2 weeks P otential for: • Flexibility in dosing schedules • Combination with IMA402 with or without ICI • Phase 1a dose escalation completed • IMA401/IMA402 combination cohort in sqNSCLC is now enrolling at multiple clinical trial sites, with first data expected in 2027 TCER® IMA401 MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 Tolerability Activity & Duration of Response 1 Development Potential Pharmacokinetics • Phase 1a dose escalation completed • IMA401/IMA402 combination cohort in sqNSCLC is now enrolling at multiple clinical trial sites, with first data expected in 2027
Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors 52 EudraCT No 2021 - 004326 - 30; NCT05359445; a Step dosing introduced at dose levels ≥1 mg, low - dose dexamethasone partially used as preventive measure for initial doses as ap plied for other bispecific T - cell engagers; ability to increase dose to previously cleared dose levels; b q2w: once every two weeks, weekly (q1w) IMA401 dosing was applied up to 0.54 mg; c MTD was not reached at 2.5 mg as defined by the adaptive BLRM model specifying probabilities of DLTs at tested doses. BLRM, Bayesian logistic regression model; ICI, immune checkpoint in hibitor; IV, intravenous; MABEL, minimum anticipated biological effect level; MTD, maximum tolerated dose, RP2D, recommended phase 2 dose; q6w, every 6 weeks. Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 0.18 mg 0.54 mg 1.8 mg 0.06 mg 1.2 mg 0.02 mg 0.0066 mg 2.0 mg 1.0 mg 1.5 mg 2.5 mg Phase 1a dose escalation completed 1.8 mg 1.2 mg 2.0 mg 1.0 mg 1.5 mg Dose selection : MTD not reached per adaptive BLRM model c , RP2D defined at 1 - 2 mg based on optimal risk - benefit - profile 1.0 mg 1.5 mg + Pembrolizumab + Pembrolizumab ICI combination : Pembrolizumab started 1 week before IMA401 (400 mg IV q6w) • MABEL - based starting dose • Dose escalation based ​on cohorts of 1 - 6 patients using ​ adaptive design (BLRM model)​ • Initial q1w step dosing a (2 - 4 doses) up to target dose, q2w after reaching target dose b Phase 1a Dose Escalation 0.0066 mg - 2.5 mg IMA401 ( n=61 ) RP2D Selection 1.0 - 2.0 mg IMA401 ( n=32 ) ICI Combination at RP2D 1.0 or 1.5 mg IMA401 with Pembrolizumab ( n=12 ) RP2D selection completed IMA401 + ICI completed MAGEA4/8 Bispecific IMA401
Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors 53 a Includes small molecule drugs and antibodies . b IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); adNSCLC , adenocarcinoma non - small cell lung cancer ; ECOG, Eastern Cooperative Oncology Group; GCT, germ cell tumor; H&N, head and neck ; HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor ; LCNEC, large cell neuroendocrine carcinoma; LDH, lactate dehydrogenase ; NET CUP, neuroendocrine tumor of cancer of unknown primary ; RP2D, recommended phase 2 dose; SCLC, small cell lung cancer ; SLD, sum of longest diameter(s); sqNSCLC , squamous cell non - small cell lung cancer ; TNBC, triple - negative breast cancer ; ULN, upper limit of normal. Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 RP2D (1 - 2 mg) All Dose Levels Baseline Characteristics IMA401 + Pembrolizumab b n=12 IMA401 (Monotherapy) n=32 IMA401 ± Pembrolizumab n=61 63 (33, 77) 62 (19, 82) 62 (19, 82) Age (years) , median (min, max) 12 (100)/ 0 (0) 19 (59)/ 13 (41) 39 (64)/ 22 (36) Sex , m ale/female n (%) 6 (42) 6 (50) 0 11 (34) 20 (63) 1 (3) 21 (34) 38 (62) 2 (3) ECOG performance status 0, n (%) 1, n (%) 2, n (%) 8 (67) 4 (33) 0 17 (53) 14 (44) 1 (3) 36 (59) 21 (34) 4 (7) LDH at baseline < 1xULN, n (%) 1 - 2xULN, n (%) > 2xULN, n (%) 63.1 (15.5, 121.0) 60 (11.3, 202.8) 67 (11.3, 202.8) Baseline tumor burden Target lesion SLD [mm], median (range) 4.5 (2, 10) 4 (33) 0 4 (1, 10) 10 (31) 2 (6) 4 (1, 10) 18 (30) 4 (7) Tumor lesions Number of lesions, median (min, max) Liver metastases, n (%) Brain metastases, n (%) Treatment Experience 3 (1, 4) 4 (1, 8) 3 (1, 8) No. of prior lines of systemic treatment median (min, max) 11 (92) 11 (92) 9 (75) 0 0 25 (78) 18 (56) 22 (69) 2 (6) 4 (13) 52 (85) 40 (66) 41 (67) 4 (7) 7 (11) Prior treatments, n (%) Chemotherapy ICI Targeted Therapy a Hormone Therapy Others Highly heterogenous patient population with >15 different indications # of Patients Different Indications (all dose levels) 16 H&N (squamous, adenocarcinoma, others) 8 Melanoma (Cutaneous & Mucosal) 8 Synovial Sarcoma 4 sqNSCLC 4 TNBC 3 adNSCLC 3 Ovarian Carcinoma 2 Gastric Cancer 2 SCLC 2 Urothelial Carcinoma 1 Bladder Carcinoma 1 Esophageal Carcinoma 1 Gallbladder Adenocarcinoma 1 LCNEC Esophageal 1 LCNEC Lung 1 NET CUP 1 Non - melanoma Skin Cancer (Squamous) 1 Penile Cancer 1 Testicular GCT MAGEA4/8 Bispecific IMA401
Tolerability of IMA401 Monotherapy 54 a All TRAEs at least possibly related to IMA401 infusion and / or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all patients , all events with ≥ grade 3; b in patients with and without dexamethasone pre - medication , one possibly related death (pneumonia in the context of lung tumor progression and concurrent neutropenia) as previously reported , patient did not receive dexamethasone pre - medication ; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CSF, colony - stimulating factor , CRS, cytokine release syndrome , DLT, dose - limiting toxicity ; ICANS, immune effector cell - associated neurotoxicity syndrome ; GGT, gamma - glutamyltransferase ; MoA , mechanism of action ; RP2D, recommended phase 2 dose; TRAE, treatment - related adverse event . Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 • Most common AEs: • Low - grade CRS (38% G1 - G2, no ≥G3 ), mainly at first step dose, resolving within 1 - 3 days • Transient, mechanism - related lymphopenia • Mostly transient neutropenia, manageable with dexamethasone and G - CSF; not recurring after resolution with continued IMA401 treatment • No ICANS observed • MTD not reached • Neutropenia - related DLTs in 5 patients (incl. 3 at >RP2D b ) • No DLTs at RP2D with dexamethasone premedication Manageable tolerability profile with mostly transient AEs, consistent with MoA IMA401 (Monotherapy) A ll treated patients > 2 mg n=7 1 - 2 mg (RP2D) n=32 All Dose Levels N=61 Treatment - related Adverse Events (safety analysis set) ≥ Grade 3 All Grades ≥ Grade 3 All Grades ≥ Grade 3 All Grades TRAEs a , n (%) 7 (100) 7 (100) 16 (50) 28 (88) 31 (51) 54 (89) Any TRAE 0 3 (43) 0 12 (38) 0 23 (38) Cytokine release syndrome 5 (71) 5 (71) 7 (22) 9 (28) 16 (26) 20 (33) Lymphopenia 5 (71) 5 (71) 5 (16) 11 (34) 11 (18) 19 (31) Neutropenia 2 (29) 3 (43) 0 5 (16) 2 (3) 10 (16) Thrombocytopenia 1 (14) 1 (14) 4 (13) 7 (22) 5 (8) 9 (15) Leukopenia 1 (14) 2 (29) 1 (3) 7 (22) 2 (3) 9 (15) Headache 3 (43) 4 (57) 2 (6) 2 (6) 7 (11) 8 (13) Anaemia 1 (14) 4 (57) 0 0 2 (3) 7 (11) Facial pain 0 1 (14) 1 (3) 3 (9) 1 (2) 7 (11) ALT increased 0 1 (14) 0 2 (6) 0 7 (11) Pyrexia 0 0 2 (6) 3 (9) 3 (5) 5 (8) AST increased 0 0 2 (6) 3 (9) 2 (3) 4 (7) Hypertension 0 0 0 0 1 (2) 2 (3) GGT increased 0 0 0 0 1 (2) 2 (3) Hypoxia 0 0 1 (3) 1 (3) 1 (2) 1 (2) C - reactive protein increased 0 0 0 0 1 (2) 1 (2) Chest pain 1 (14) 1 (14) 0 0 1 (2) 1 (2) Febrile neutropenia 1 (14) 1 (14) 0 0 1 (2) 1 (2) Pneumonia 0 0 1 (3) 1 (3) 1 (2) 1 (2) Sinus tachycardia MAGEA4/8 Bispecific IMA401
Tolerability of IMA401 at RP2D ± Pembrolizumab 55 a All TRAEs at least possibly related to IMA401 infusion and / or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all patients , all events with ≥ grade 3 and typical ICI - associated toxicities ; b IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); ICI, immune checkpoint inhibitor ; RP2D, recommended phase 2 dose; TRAE, treatment - related adverse event . Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 No overlapping and/or additive toxicity observed in the combination cohort, supporting IMA401 combinability with ICIs. IMA401 + Pembrolizumab IMA401 (Monotherapy) 1 - 2 mg (RP2D) b n=12 1 - 2 mg (RP2D) n=32 Treatment - related Adverse Events (safety analysis set) ≥ Grade 3 All Grades ≥ Grade 3 All Grades TRAEs a , n (%) 3 (25) 11 (92) 16 (50) 28 (88) Any TRAE 0 5 (42) 0 12 (38) Cytokine release syndrome 2 (17) 4 (33) 7 (22) 9 (28) Lymphopenia 0 1 (8) 5 (16) 11 (34) Neutropenia 0 1 (8) 0 5 (16) Thrombocytopenia 0 1 (8) 4 (13) 7 (22) Leukopenia 0 0 1 (3) 7 (22) Headache 0 0 2 (6) 2 (6) Anaemia 0 0 0 0 Facial pain 0 2 (17) 1 (3) 3 (9) Alanine aminotransferase increased 0 3 (25) 0 2 (6) Pyrexia 0 1 (8) 2 (6) 3 (9) Aspartate aminotransferase increased 0 0 2 (6) 3 (9) Hypertension 1 (8) 1 (8) 0 0 Gamma - glutamyltransferase increased 0 0 0 0 Hypoxia 0 0 1 (3) 1 (3) C - reactive protein increased 0 0 0 0 Chest pain 0 0 0 0 Febrile neutropenia 0 0 0 0 Pneumonia 0 0 1 (3) 1 (3) Sinus tachycardia Any group analyzed ICI - associated toxicities 0 Immune - mediated colitis 0 Immune - mediated pneumonitis 0 Immune - mediated hepatitis 0 Nephritis 0 Adrenal insufficiency 0 Immune - mediated hypophysitis MAGEA4/8 Bispecific IMA401
Anti - Tumor Activity of IMA401 at RP2D ± Pembrolizumab 56 Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pe mbrolizumab infusion in combination therapy and had a post - baseline efficacy assessment, including patients with clinical progression; a Two patients not shown in plot due to clinical progression before post - infusion scan. b One patient not shown in plot due to clinical progression before post - infusion scan. BOR, best overall response; (c)ORR, (confirmed) objective response rate; (c)PR, (confirmed) partial response ; DCR, disease control rate; H&N, head and neck cancer; PD, progressive disease; PFS, progression - free survival; RECIST, response evaluation criteria in solid tumors; RP2D, recommended phase 2 dose; SD, stable disease; OS, overall survival; mDOR , median duration of response. Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 H&N b ( n= 14) BOR (RECIST 1.1) PD SD PR cPR Ongoing response /disease control Other a (n=27, 14 different indications) IMA401 monotherapy IMA401 + Pembrolizumab 29 % ( 4/14 ) cORR 64% (9/14) DCR H&N (n=14) sqNSCLC Cut. Melanoma Cut. Melanoma Muc . Melanoma NET CUP Penile Cancer All H&N responders achieved deep responses with 60% - 100% tumor reduction MAGEA4/8 Bispecific IMA401
Durable Responses to IMA401 ± Pembrolizumab in Patients with H&N Cancer 57 Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pe mbrolizumab infusion in combination therapy and had a post - baseline efficacy assessment, including patients with clinical progression; a One patient not shown in plot due to clinical progression before post - infusion scan. BOR, best overall response; cPR , confirmed partial response; DOR, duration of response; H&N, head and neck cancer; PD, progressive disease; PR, partial response; RECIST, response evaluation c rit eria in solid tumors; RP2D, recommended phase 2 dose; SD, stable disease. Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026  0 6 12 18 24 -100 -50 0 50 100 Months post First IMA401 Infusion C h a n g e i n S u m o f L o n g e s t D i a m e t e r o f T a r g e t L e s i o n s f r o m B a s e l i n e [ % ] BL PR ⯈ Palliative Radiotherapy + ⯈ ⯈ ⯈ ⯈     n=14 a IMA401 + Pembrolizumab 8.8 mo mDOR 63% 43% 12m OS rate 6m PFS rate 3 of 4 responses ongoing at data cutoff MAGEA4/8 Bispecific IMA401
Patient Case: Partial Response after IMA401 + Pembrolizumab in sqNSCLC 58 a Treatment start 5 weeks after last prior systemic therapy; scans courtesy of treating physician Prof. Dr. Martin Wermke , TU Dresden; BOR, best overall response; ICI, immune checkpoint inhibitor; PR, partial response; Pt, patient; Q6W, once every 6 weeks; SD, stable disease; sqNSCLC, squamous cell non - small cell lung cance r. Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 Lung Baseline 7 weeks Jaw Head Head PR with IMA401 in 5 th line ICI - resistant sqNSCLC patient with shrinkage of all target lesions Patient Characteristics & Outcome 63 - year - old male with ICI - resistant sqNSCLC ; initial diagnosis in July 2018 Patient & Diagnosis Multiple metastases i n lymph nodes, skin, lung and bone Disease at Baseline 4 prior lines of systemic therapy with BOR SD • Adjuvant: cisplatin, vinorelbine • Carboplatin, ipilimumab, nivolumab, paclitaxel, BOR: SD • Docetaxel, ramucirumab, BOR: SD • Progressed after all prior treatments • Carboplatin, gemcitabine, BOR: SD, discontinued early due to toxicity Prior systemic therapy 1 mg IMA401 + 400 mg pembrolizumab Q6W; Pt died during a biopsy due to pulmonary haemorrhage Study Treatment a PR at first scan post IMA401 treatment start with - 39% tumor reduction Response Assessment MAGEA4/8 Bispecific IMA401
Appendix Making a Meaningful Impact on the Lives of Patients with Cancer www.immatics.com
Anzu - cel Ph1 Trial: Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS of 16 Months in Melanoma Efficacy Population 60 Progression Free Survival Data cutoff Sep 24, 2025 Overall Survival mPFS N 2.6 months 11 Dose Escalation 6.1 months 33 Dose Expansion mOS N 6.3 months 11 Dose Escalation 16.2 months 33 Dose Expansion • Significant shift in mPFS and mOS between melanoma patients treated during the dose escalation and dose expansion • mPFS in dose escalation is comparable to reported data in 2L+ cut. melanoma population * • mOS in dose escalation is shorter than reported mOS for 2L+ cut. melanoma population * • All patients in the dose escalation group deceased and 9 /23 evaluable patients are alive in dose expansion # Log - rank test: p <0.0001 Log - rank test: p <0.0001 Anzutresgene autoleucel (anzu - cel, formerly IMA203), Overall survival (OS) and progression - free survival (PFS) censored at data - cut; * These data are derived from different clinical trials at different points in time with differences in trial design and patient populations. As a result, cross - trial comparisons cannot b e made, and no head - to - head clinical trials have been conducted # 10 patients out of study at data - cut (withdrew consent) PRAME Wave 1: anzu - cel
Potential of PRAME - Directed Therapies in Solid Cancers PRAME Target Expression and Prevalences in Selected Solid Cancer Types Hukelmann et al., SITC 2022, updated prevalences as of May 2025; a Data on file: PRAME target prevalence is based on a proprietary mass spec - guided initial expression threshold applied to TCGA or in - house (SCL C) RNAseq data (approximate values, values between 95 - 100% shown as 95%); b Presumed optimized threshold used for combination approaches (e.g. IMA402/IMA401) and cell therapies, including anzu - cel and IMA203CD8. c PRAME target prevalence in uveal melanoma based on IMADetect® qPCR testing of screening biopsies from clinical trial patients demonstrates substantial higher prevalence of ~90% compared to prevalence based on TCGA data of 50%, TCGA: early & late - stage pr imary tumor samples, Immatics clinical trials: late - stage/metastatic tumor samples, Role of PRAME in metastasis of uveal melanoma: Field et al. 2016 Clinical Cancer Research; MS: mass spectrometry; NSCLC: non - small cell lung cancer Selected indications Clinical activity shown No clinical activity expected Potential for clinical activity 95% 90% (50% c ) 95% 85% 95% 95% 70% 65% 45% 40% 35% 25% 25% 25% 25% 20% 20% Cutaneous Melanoma Uveal Melanoma c Uterine Carcinoma Ovarian Carcinoma (serous) Uterine Carcinosarcoma Synovial Sarcoma Squamous Cell NSCLC Triple - negative Breast Carcinoma Small Cell Lung Cancer Kidney Carcinoma (papillary) Cholangiocarcinoma Adenocarcinoma NSCLC Breast Carcinoma (all subtypes) Head & Neck Squamous Cell Carcinoma Esophageal Carcinoma (all subtypes) Hepatocellular Carcinoma Bladder Carcinoma Initial threshold to determine PRAME positive patients in current clinical trials a Presumed optimized threshold b 61 PRAME
IMA203CD8 Shows Broad Clinical Activity across Diverse PRAME+ Solid Tumors Clinical Activity in PRAME+ T umors with D istinct P athology / Biology 62 Clinical activity to date spans different PRAME levels, tumor biologies and tumor immune phenotypes, supporting broad applicability of IMA203CD8 for PRAME+ solid tumors, beyond the ones investigated a Hot = T cell infiltrated/inflamed; Cold = non - T - cell infiltrated /non - inflamed according to Galon and Bruni, Nat Rev Drug Discov , 2019 . Dominant phenotype for a tumor indication shown, intermediate “altered” immunological phenotypes not assessed for simplicity. Mixed: larger fractions of molecular subtypes ex ist with both, hot and cold immunological phenotype PRAME Wave 2: IMA203CD8 Clinical Activity Immunological phenotype a Relative PRAME Expression Hot High Melanoma Mixed High Uterine cancer Cold High Synovial sarcoma / Uveal melanoma Cold Low Ovarian carcinoma x x x Busse et al, ESMO 2026 Busse et al, ESMO 2026 Busse et al, ESMO 2026 x Busse et al, ESMO 2026
Thank you! Making a Meaningful Impact on the Lives of Patients with Cancer www.immatics.com